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ABSTRACT 
Kristen L. Hosey 
THE ROLE OF STAT1 IN CHLAMYDIA-INDUCED TYPE I INTERFERON 
RESPONSES IN OVIDUCT EPITHELIUM 
 Progression of Chlamydia into upper reproductive tract epithelium and the 
induction of subsequent immune responses to infection are major contributors to 
Chlamydia-induced pathogenesis of the genital tract. We reported that C. muridarum 
infection of the oviduct epithelial cells (OEs) secrete IFN-β in a TLR3 dependent manner. 
However, we showed that the C. muridarum infected TLR3-deficient OEs were still able 
to secrete minimal amounts of IFN-β into the supernatants, which is suggestive that there 
are other signaling pathways that contribute to Chlamydia-induced IFN-β synthesis in 
these cells. Previous studies describing the activation of the JAK/STAT signaling 
pathway during Chlamydia infection of cervical epithelial cells proposes a putative role 
for STAT1 in the synthesis of type I IFNs during Chlamydia infection. The present study 
investigated the role of STAT1 in Chlamydia-induced IFN-β production in OEs. OEs 
were infected with Chlamydia muridarum and analyzed at 24 hours by RT-PCR and 
western blot to determine STAT1 expression. STAT (-/-) OEs were infected and IFN-β 
production measured by ELISA. Quantitative real-time PCR analyses were performed at 
6 and 16 hour post-infection to elucidate the mechanisms involved in IFN-β production 
during infection. Fluorescent microscopy was used to observe changes in Chlamydia 
replication. STAT1 activation and expression were significantly increased in wild-type 
(WT) OEs upon infection. TLR3 (-/-) OEs showed diminished STAT1 protein activation 
and expression. Augmented STAT1 protein expression corresponded to STAT1 mRNA 
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levels. ELISA analyses revealed significantly less IFN-β production in infected STAT1 (-
/-) OEs compared to WT OEs. Quantitative real-time PCR data showed that gene 
expression of IFN-β and of type I IFN signaling components were significantly increased 
during late stage Chlamydia infection, dependent on STAT1. Temporal regulation and 
increases in expression of IFN-α subtypes during infection were STAT1-dependent. Our 
results implicate STAT1-mediated signaling as a contributor to the C. muridarum-
induced synthesis of IFN-β and other type I IFNs in OEs. We previously described a 
major role for TLR3 in the early-stage Chlamydia-induced synthesis of IFN-β in OEs; the 
results from this study suggest a role for STAT1 in the synthesis of type I IFNs that 
occurs during early and late stages of infection. 
 
 
Wilbert A. Derbigny, Ph.D., Chair  
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INTRODUCTION 
I. Chlamydia trachomatis 
 Chlamydiaceae are obligate intracellular parasites that were once considered to be 
viruses because they are small enough to pass through 45 μm filters. Historically, the 
family Chlamydiaceae consisted of one genus, Chlamydia, in which all species were 
grouped [1-4]. However, based on genomic studies, the family was divided into two 
genera, Chlamydia and Chlamydophila [5-8]. There are three species within the 
Chlamydiaceae family that exist as pathogenic organisms capable of causing human 
disease including: Chlamydia pneumonia (respiratory illnesses and cardiovascular 
disease), Chlamydia psittaci (zoonotic pneumonia), and Chlamydia trachomatis (genital 
tract infections and trachoma) [9]. The Chlamydia genera consist of other pathogenic 
members that cause clinical disease in animals including the mouse homolog Chlamydia 
muridarum (C. muridarum; formally known as C. trachomatis mouse pneumonitis 
(MoPn)); and Chlamydia suis the swine homolog.  
 C. trachomatis is a gram-negative, obligate intracellular bacterium [2, 10]. 
Though Chlamyida trachomatis is capable of infecting classical immune cells such as 
macrophages (Φ), dendritic cells (DCs) [11-13], as well as fibroblasts [14, 15]; C. 
trachomatis infections are restricted to humans, primarily to the non-ciliated epithelial 
cells of the respiratory tract, conjunctivae, mucosa, and urogenital tract [16, 17]. Based 
on specific host restrictions, the C. trachomatis species were further divided into two 
biovars: (i) the trachoma biovar that is associated with trachoma or primary infection of 
the conjunctiva (eye infections), and (ii) the lymphogranuloma venereum (LGV) biovar 
which are urogenital infections that primarily affect the inguinal lymph nodes. Antigenic 
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variations in the major outer membrane proteins (MOMP) of these biovars called for 
furtherdivision into serovars that were associated with a specific disease [18, 19]. 
Serovars Ab, B, Ba, and C are associated with trachoma. Serovars L1-L3 are associated 
with LGV. Serovars D-K are associated with primary urogenital tract infections and 
Chlamydia-associated reactive arthritis [20]. 
 Unlike other bacteria, the Chlamydiaceae have a unique developmental cycle 
whereby it can exist in either of two forms: an infectious, non-metabolically active 
elementary body (EB) and the non-infectious, metabolically active reticulate body (RB) 
[21, 22]. These EBs and RBs comprise the biphasic replication cycle part of all 
Chlamydia species (Figure 1). A typical Chlamydia developmental cycle begins by rapid 
attachment and entry of the EB into the host cell via a poorly understood receptor-
mediated endocytosis pathway, followed by the recruitment of components of the host 
cell cytoskeleton that results in the formation of an intracellular vesicle containing the 
infectious EB known as the inclusion body. Chlamydia EBs express cysteine-rich outer 
membrane proteins and complexes (i.e. OmcA, OmcB) that reversibly interact with host 
surface glycosaminoglycans [23, 24], followed by an irreversible attachment to 
components of host estrogen receptors [25, 26]. EBs also presumably express preformed 
Type III Secretion Systems (TTSS) that export Chlamydial signaling molecules to the 
host cell as a means to recruit actin that aids in EB entry and ultimately, trafficking of the 
inclusion body to the peri-Golgi region of the host cell [27, 28]. The EBs undergo 
primary differentiation to the metabolically active RB; a process initiated by the 
disruption of deoxyribonucleic acid (DNA)-histone interactions, presumably by 
Chlamydia metabolites [29]. Primary differentiation involves modification of the 
3 
inclusion body through a process regulated by Chlamydia inclusion membrane (Inc) 
proteins, and the interception of vacuoles containing sphingomyelin, cholesterol, and 
endocytic GTPases from endocytic/exocytic pathways [30-34]. Rapid replication of the 
RBs to identical progeny occurs and continues via binary fission from 6- 24 hours, and 
the number of progeny is normally directly proportional to the growth of the inclusion 
body [22]. The secondary differentiation involves the redifferentiation of the newly 
synthesized RBs to EBs. This stage is marked by increases in Omc genes and histone-like 
proteins and by down-regulation of components of the TTSS system [35, 36]. At 48-72 
hours the EBs are subsequently released from the host cell via cell lysis, where they are 
free to re-infect neighboring cells and thereby repeat the replication cycle.
4 
 
Figure 1. The Chlamydia replication cycle 
 Chlamydia undergoes a unique, biphasic replication cycle upon infection. The 
infectious EB attaches to and enters the host cell via receptor-mediated endocytosis. Once 
inside the cell the EB remains in an intracellular inclusion forming unit and begins to 
enter a primary differentiation stage where the EB differentiates to the metabolically 
active, noninfectious RB. The RB divides via binary fission and rapidly produces 
identical progeny RBs. Note that the structure containing the newly-formed RBs is now 
termed an inclusion body (IB). Near the end of the infection cycle newly synthesized RBs 
undergo a secondary differentiation stage where they redifferentiate to the infectious EBs. 
The host cell is lysed and the infectious EBs released; reinitiating the infectious cycle in 
neighboring cells. Figure adapted from [22].
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II. C. trachomatis Urogenital Serovars D-K 
 C. trachomatis is the most common bacterial sexually transmitted disease in the 
United States [37]. It is estimated by the World Health Organization that 90 million of 
the 500 million new cases of sexually transmitted diseases (STDs) per year, are caused by 
C. trachomatis serovars D to K [38]; with the highest prevalence among women from 
ages 15-25 [39]. Progression of C. trachomatis infection into the upper reproductive tract 
epithelium causes significant inflammation [40-44]. In women, chronic infections with 
urogenital serovars of C. trachomatis and progression of Chlamydia into the upper 
reproductive tract epithelium can cause pelvic inflammatory disease (PID), scarring, and 
infertility [42, 43, 45, 46], all of which are irreversible. Estimated incidences of 
Chlamydia-associated ectopic pregnancies and tubal infertility ranges from 5-25%, and 
10-20%, respectively [47]. The annual costs of treating sexually transmitted diseases in 
the United States is approximately 15.9 billion dollars; with Chlamydia-related costs 
estimated to almost 2.4 billion dollars and steadily increasing [48, 49]. 
 Chlamydia urogenital infections are curable via oral administration of antibiotics. 
A single-dose regimen of the macrolid antibiotic azithromycin, or a multi-dose regimen 
of the tetracycline antibiotic doxycycline are equally efficacious in treating Chlamydia 
urogenital infections [50-54]. However, C. trachomatis genital infections are clinically 
asymptomatic and are thus a major public health concern [55]. Reports indicate that 
approximately 75% of women and up to 50% of men show no clinical signs or symptoms 
upon Chlamydia infection [37, 56-58], and up to 40% of asymptomatic women will 
develop PID due to lack of treatment and progression of C. trachomatis into upper 
reproductive tract epithelium [37, 58, 59]. The inability to detect clinical manifestations 
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of C. trachomatis infections contributes, significantly, to the deleterious post-infection 
sequealae and increased transmission between sexual partners. The development of an 
immunization regimen that efficiently combats C. trachomatis is warranted and has the 
potential of decreasing Chlamydia prevalence worldwide. 
 Early trials of candidate Chlamydia vaccines revealed a short-lived protective 
immune response with increased post-infection sequealae. These early candidate vaccines 
included both live attenuated, and heat-inactivated whole organisms of Chlamydia which 
were capable of inducing host immune responses similar to natural infections, albeit for  
a limited time and at suboptimal levels. However, the vaccines exposed the host to 
antigens or virulent factors that contributed to host pathology [60-64]. In later Chlamydia 
vaccine trials a subunit-approach was used to generate candidate vaccines. The subunit 
vaccines were proposed to be advantageous due to lack of host exposure to the virulent 
factors that induced immunopathology; however these vaccines proved to be incapable of 
inducing a strong cell-mediated response, which is a major requirement for protective 
immunity against Chlamydia [63, 65-72]. More recently DNA-based vaccines have been 
generated and current studies using a combinational approach (i.e. DNA-based and 
subunit-based vaccines) show that this strategy for Chlamydia vaccination evoked both 
humoral and cell-mediated protective immune responses without significantly increasing 
the immunopathology as seen with earlier vaccine candidates [63, 73-77]. Thus, the 
development of an efficacious vaccine requires in depth understanding of the 
immunologic mechanisms that evoke both protective and pathological responses during 
Chlamydia infection; particularly in reproductive epithelium. 
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III. C. trachomatis-induced Host Immune Responses  
 The host immunological responses to C. trachomatis infections vary among 
biovars. While trachoma serovars predominantly induce cell-mediated immune responses 
contributing to delayed hypersensitivity (a possible evasion mechanism), the LGV 
serovars induce initial cellular immune responses, followed by a strong cell-mediated and 
humoral adaptive immune response [78-82]. Furthermore, Dessus-Babus, et al, in a study 
comparing LGV serovar L2 and urogenital serovar E, showed that HeLa 229 cells 
induced with these serovars displayed different innate immune responses [83]. Most of 
the details of Chlamydia-induced immune responses and the mechanisms that are 
implicated in both clearance and pathology have been unveiled in mouse models of 
Chlamydia genital infections using C. muridarum [84-87]. Though there have been some 
major differences cited in C. muridarum genital infections in mice versus C. trachomatis 
genital infections in humans, including: differences in infection duration/clearance rates, 
differences in immune evasion mechanisms, and differences in allelelic variation of the 
MOMP antigen [84, 86, 88-91], the immune responses in experimental mouse models of 
C.muridarum vaginal infections closely mimics those of natural acute C. trachomatis 
vaginal infections in humans [85, 87, 92, 93]; and thus serve as a useful tool in 
elucidating the immunobiology of C. trachomatis gential tract infections. 
 Though mucosal barriers of the genital tract provide the first line of defense, 
epithelial cells lining the genital tract act as sentinels for invading Chlamydia trachomatis 
infection. Classically, epithelial cells were not thought to be critical players in innate 
immunity. However, the resulting immune responses to Chlamydia infection in epithelial 
cells included the production and secretion of several cytokines and chemokines required 
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for several host adaptive functions such as restricting the pathogen and 
recruiting/activating innate immune cells {natural killer cells (NKs), Φ, DCs}, and 
adaptive immune cells {naïve T-lymphocytes (T-cells) and B-lymphocytes (B-cells)} to 
the sites of infection [17, 94-100]. Chlamydia-infected epithelial cells have been shown 
to secrete acute-phase pro-inflammatory cytokines and chemokines such as interleukin-1 
(IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), CXC-chemokine ligand 1(CXCL1), 
CXC-chemokine ligand 16 (CXCL16), CC-chemokine ligand 5 (CCL5 or Rantes), and 
granulocyte/monocyte colony-stimulating factor (GM-CSF) [17, 44, 84, 95, 99]. It has 
also been demonstrated during C. trachomatis infection, that immunomodulatory 
cytokines such as the type I IFNs, IFN-α and IFN-β, interleukin-10 (IL-10), interleukin-
12 (IL-12) and tumor necrosis factor-alpha (TNF-α), are all up-regulated in both the 
cervix and the fallopian tubes [44, 101]. Studies have also shown increased secretion of 
mature interleukin-18 (IL-18), a potent inducer of the type II IFN interferon-gamma 
(IFN-γ) in infected human epithelial cells, via a caspase-1-dependent mechanism [102]. 
The ultimate clearance and control of Chlamydia infections are dominated by IFN-γ [85, 
103-105]. IFN-γ is a cytokine produced by classical innate immune cells and adaptive 
immune cells that is induced and regulated by acute-phase or innate chemokines and 
cytokines including IFN-α and IFN-β [44, 84, 106, 107]. The majority of these 
chemokines and cytokines promote T helper 1 (TH-1) protective immunity, resulting 
predominately in CD4
+
 T-cell-mediated resolution of Chlamydia infection [84, 108, 109]; 
although CD8
+
 T-cells have been implicated [110, 111]. These findings implicate the 
epithelial cell cytokine response as a major contributor to host protective immunity 
during Chlamydia infections. 
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 In mammalian cells, the invasion of microorganisms is sensed via a specialized 
family of membrane bound PRRs called Toll-like receptors (TLRs) [112, 113]. The TLRs 
are stimulated by the recognition of pathogen-associated molecular patterns (PAMPs) 
that result in the synthesis of acute inflammatory cytokines and chemokines including 
CCL5, IL-6, GM-CSF, IL-1β and type I IFNs [17, 112, 114, 115]. TLRs transduce 
signals initiated by binding of a distinct PAMP to the leucine-rich repeat-containing 
ectodomains, followed by propagation via the transmembrane domains, and ultimately 
via the intracellular Toll-IL-1 receptor (TIR) domain for efficient downstream signal 
transduction [112, 113, 116, 117]. In mammals there are at least 13 TLRs that recognize 
specific PAMPs; of which TLRs 1-9 are conserved among human and murine species, 
with 10 functional TLRs in humans (1-10) and 12 functional TLRs in mice (1-9, 11-13) 
[113, 114, 118]. PAMPs recognized by TLRs are derived from various microbes 
including: bacteria, viruses, fungi and parasites and are recognized based partly on the 
cellular location of the TLR [112, 113, 117]. Cell surface TLRs, TLR1, TLR2, TLR4, 
TLR5, TLR6, and TLR11 recognize microbial components such as lipoproteins (LP), 
petidoglycan (PGN), lipopolysaccharide (LPS), flagellin and uropathogenic components; 
respectively. TLRs 3, 7, 8, and 9 are located intracellularly within endosomal vesicles 
and recognize nucleic acids such as double-stranded ribonucleic acid (dsRNA), single-
stranded RNA (ssRNA), and unmethylated 2′-deoxyribo-cytidine-phosphateguanosine 
(CpG) DNA; respectively [113, 116, 119-126]. Distinct immune responses (i.e. 
inflammatory cytokine production, type I IFN production) induced by individual TLRs 
are also attributed to the recruitment of distinct TIR-domain containing adaptor 
molecules such as TIR-domain-containing adaptor protein (TIRAP), myeloid 
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differentiation primary response gene 88 (MyD88), TIR-domain-containing adapter-
inducing interferon-β (TRIF), TRIP-related adaptor molecule (TRAM), TNF receptor 
associated factors (TRAFs); the subsequent activation of specific kinases such as IL-1 
receptor–associated kinases (IRAKs), transforming growth factor-beta–activated kinase 1 
(TAK1), TRAF-associated NF-κB activator (TANK)-binding kinase 1 (TBK1), inhibitor 
of kappa B kinases (IKKs), mitogen-activated protein kinases (MAPKs); and 
transcription factors nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB), activator protein 1 (AP-1), and interferon regulatory factor 3 (IRF3) [116, 122, 127-
132]. In addition, other non-TLR PRRs such as retinoic acid-inducible gene 1 (RIG-1)-
like receptors (RLRs), nucleotide oligomerization domain (NOD)-like receptors (NLRs), 
inflammasomes and recently identified double-stranded DNA (dsDNA) sensors localized 
throughout the cytosol are also activated by PAMPs derived from viruses and 
intracellular bacteria, to initiate the appropriate immune responses [113, 133-1°]. 
 Studies in DCs have led investigators to theorize that differential expression of 
TLRs, both at the cell surface and in endosomal compartments, heavily influences the 
type of immune responses induced by microbial pathogens [113, 138]. In macrophages 
activated by bacteria, both TLR2 and TLR4 mediate the secretion of proinflammatory 
cytokines as demonstrated by the ability of heat-killed Staphylococcus aureus to induce 
NF-κB activation in human monocytes, and the inability to activate NF-κB in TLR4-
deficient macrophages upon induction, respectively [139-142]. Applequist et al, 
demonstrated that many of the classical innate immune cells of myeloid lineage express a 
wide variety of TLRs, whereas the cells involved in adaptive immune responses and of 
lymphoid lineage selectively expressed TLRs based on cellular location [143]. TLRs are 
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also differentially expressed on nonimmune cells that contribute to inflammatory and 
immunoregulatory responses. Previous studies in humans have shown that both primary 
and transformed uterine epithelial cells express TLRs 1-9 [144, 145], while primary and 
immortalized cervical epithelial cells express TLRs 1-6 lacking TLR4 expression [146], 
and Fallopian tube tissue homogenates to express TLR2 and TLR4 [147]. Intestinal 
epithelial cells express TLR4 at relatively low levels [148]. It is important to note that the 
expression of TLRs can be modulated directly by microbial PAMPs or indirectly by 
autocrine signaling of secreted chemokines and cytokines [149-152]. 
 The role of TLRs in Chlamydia-induced host immune responses have been 
extensively studied. C. trachomatis-induced IL-8 production in cervical carcinomas and 
kidney epithelial cells has been shown to require functional MyD88 and TLR2 [153]. In 
Chlamydia pneumoniae-induced DCs, TLR2 has been shown to be involved in initiating 
the production of innate chemokines and cytokines [154]. TLR2 has also been shown to 
mediate proinflammatory cytokine production in C. muridarum-induced oviduct 
epithelial cells via a MyD88-dependent mechanism [155]; and is implicated in C. 
muridarum-induced fallopian tube pathology [156]. Though TLR2 is predominantly 
implicated in Chlamydia-induced innate immune responses, Chlamydia heat shock 
protein 60 (cHSP60) has been shown to induce NF-κB activation via TLR4 in vascular 
endothelial cells [157, 158]. Additionally, C. pnuemoniae-induced bone marrow-derived 
dendritic cells (BMDDCs) have been shown to secrete IL-12p40 dependent on TLR2 and 
TLR4 [154]. Furthermore, Chlamydia infections induce a robust IFN response via 
stimulation of TLRs. In bone marrow-derived macrophages (BMDMs) C. pneumoniae 
was shown to induce IFN-β, IFN-α, and IFN-γ genes in a MyD88/TRAF6/IRAK-4-
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dependent manner [159]. Nagarajan et al, showed an approximate 80% decrease in IFN-β 
mRNA from C. muridarum-induced MyD88-deficient peritoneal Φ compared to wild-
type peritoneal Φ [160]. Human vascular endothelial cells have also shown a dependence 
on mitochondrial antiviral signaling (MAVS) protein, an adaptor molecule involved in 
RLRs signaling; and IRF3 for IFN-β protein and gene expression in a C. pneumoniae 
infection model. A C. muridarum rat model utilizing  prostate epithelial cells was shown 
to upregulate TLR2 and TLR4 gene expression, as well as, to recruit these TLRs to the 
inclusion body and to significantly induce CXCL10 (IP-10) protein expression; a type I 
IFN-dependent gene that can serve as an indirect marker for IFN-β/α production [161]. 
Because the host immune response to Chlamydia infection results in the TLR-dependent 
synthesis of acute innate cytokines and chemokines (Figure 2) that are directly and/or 
indirectly involved in leukocyte recruitment, activation, and polarization [44, 155, 162], 
these findings highlight the importance of TLRs in the primary innate inflammatory 
response to Chlamydia infection, and in the initiation of adaptive immune responses 
required for protective immunity.
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Figure 2. Pathogen-induced TLR signaling: Chlamydia-induced innate immune 
responses in epithelial cells 
 Upon infection of epithelial cells Chlamydia PAMPs (i.e. lipoproteins, LPS) or, 
possibly, nucleic acids generated upon intracellular invasion bind to cell surface 
TLR2/TLR4 or endosomal TLR3; respectively. TLR stimulation leads to the recruitment 
and activation of cytosolic TIR domain-containing adaptor molecules, namely MyD88 
(specific to TLR2 and TLR4) and TRIF (specific to TLR3 and TLR4). These adaptors 
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and co-adapters activate specific kinases that ultimately phosphorylate/activate specific 
transcription factors (i.e. NF-κB and IRF3). Phosphorylated NF-κB and IRF3 translocate 
to the nucleus where they bind to specific promoter sequences of target genes such as Il6 
and Ifnb; respectively, and initiate transcription. In Chlamydia infections these cytokines 
have been implicated in both clearance and the associated pathologies [17, 85, 163-166]. 
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IV. Type I Interferons 
 Interferons were first identified as factors responsible for viral-induced resistance 
to infections with dissimilar viruses, termed viral interference [167, 168]. Interferons 
have since been identified as cytokines that act as antimicrobial, antiviral, and 
immunomodulatory agents during viral and intracellular bacterial infections; primarily 
functioning to restrict viral and/or bacterial replication [169-171]. In vitro and in vivo 
studies show the ability of interferons to modulate the cytotoxic activity of a variety of 
immune cells including T-cells, macrophages, NKs; and the subsequent activation of 
these cells by modulating the expression of surface molecules such as the major 
histocomapatibility complex (MHC) class I antigens [172-174]. These properties 
implicate interferons in innate and adaptive immune responses to pathogens. 
 The IFN family consists mainly of three classes: type I (namely IFN-α/IFN-β), 
type II (IFN-γ), and type III (IFN-λs) [174-176]. The type III IFNs have been closely 
compared to the type I IFN family based on their mode of signaling, however due to their 
restricted tissue distributions they were rarely studied until recently. The type II IFNs 
consist of one gene product, IFN-γ, which is induced primarily in macrophages, NKs, and 
T-cells. In contrast, type I IFNs consist of a single gene product known as IFN-β, and 
several partially homologous gene products that encode IFN-α subtypes that are 
ubiquitously produced in various cell types in response to viral and/or bacterial infections 
[177, 178]. The classes were divided accordingly based on the ability of specific 
interferons to bind to a common receptor; IFN-β and IFN-α bound to the interferon alpha 
receptor 1 and 2 (IFNAR1, IFNAR2) or type I IFN receptor, and IFN-γ bound to the 
interferon gamma receptor 1 and 2 (IFNGR1, IFNGR2) or type II IFN receptor [179-
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181]. Both classes of IFNs and the corresponding receptor upon stimulation, employ the 
use of permanently associated Janus protein tyrosine kinases. The JAKs phosphorylate 
and activate a specific set of cytoplasmic signal tranducers and activators of transcription 
(STAT) proteins that translocate to the nucleus, and act as transcriptional machinery 
inducing the transcription of IFN-stimulated genes (ISGs)  [168, 178, 182]. 
 Type I IFNs stimulate the activation of the Janus Kinases (JAK1), tyrosine kinase 
2 (TYK2), and the subsequent phosphorylation of the cytoplasmic tail of the 
heterodimeric IFNAR1 and IFNAR2 receptors. This phophorylated cytoplasmic tail of 
the receptor serves as a docking site or recruitment site for STAT1 and/STAT2, upon 
which they become phosphorylated or activated by the JAKs and form two distinct 
transcription factors consisting of  STAT1 homodimers or STAT1-STAT2 heterodimers 
complexed with interferon regulatory factor 9 (IRF9); known as the interferon-stimulated 
gene factor 3 (ISGF3). The ISGF3 complex can then translocate to the nucleus where it 
binds to a DNA sequence in the promoter region of ISGs known as the IFN-stimulated 
response element (ISRE) to initiate gene transcription [168, 169, 178, 183]. A typical 
type I IFN signaling cascade is represented in Figure 3. 
 Type I IFNs are secreted by a vast array of cell types upon pathogen recognition. 
A key requirement for the induction of type I IFNs (noteably IFN-β and IFN-α4) is the 
activation of IRF3 and interferon regulatory factor 7 (IRF7); which make up part of the 
enhanceosome, a transcription factor complex in which each component binds to specific 
promoter sequences of the IFN-β gene (Figure 4) stimulating transcripition [184-187]. 
PRRs that recognize viral or other nucleic acids are stimulated to produce type I IFNs 
[113, 116, 188]. In macrophages and some dendritic cells, TLR 3 and 4 have been 
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implicated in viral and bacterial-induced type I interferon production, respectively [116, 
189, 190]. In contrast, plasmacytoid dendritic cells (pDCs) are potent  interferon 
producers, and have been shown to produce large amounts of type I IFNs during viral 
infections; however, this production is dependent on endosomal TLRs 7 and 9, and 
signaling is mediated through MyD88 and constitutively expressed IRF7 [113, 129, 168, 
191]. Additionally, cytosolic PRRs such as RLRs have also been implicated in IRF3 
mediated type I IFN production during viral infection [178, 192]. In addition, the NLRs 
NOD1 and NOD2 can induce the production of type I IFNs in epithelial cells and 
macrophages, respectively, via novel mechanisms leading up to the activation of IRF7 
and IRF5 during bacterial infections [193, 194]. 
 Type I interferons have been shown to aid in their own production by an 
autocrine/paracrine positive feedback mechanism in which they bind to the type I 
interferon receptor of the same cell or neighboring cells, stimulating the JAK/STAT 
signaling pathway (Figure 5). The binding of type I IFNs (namely IFN-β and IFN-α4 
subtype) to the IFNAR heterodimer leads to the production or amplification of IFN-
responsive genes, including type I interferon genes via JAK/STAT signaling [168, 184]. 
The increased expression of the IRF7 protein via JAK/STAT signaling has been directly 
correlated to increased amplification of all type I IFN genes and is thought to be the 
major requirement for production or amplification of type I IFNs through this mechanism 
[195]. 
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Resting cells express a basal level of IRF7 that has been shown to be involved in the 
early stage IFN-β induction upon initial viral or intracellular bacterial infection; however, 
further expression of IRF7 was required for subsequent induction of IFN-α [184, 196-
198]. Furthermore, in vitro studies show a requirement for early stage IFN-β in the 
production of IFN-α in Listeria-induced macrophages [199].
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Figure 3. Type I IFN signaling 
 Type I IFNs (i.e. IFN-β, IFN-α) bind to the heterodimeric IFNAR1-IFNAR2 
complex stimulating the activation of permanently bound JAKs, TYK2 and JAK1. The 
activated JAKs transphosphorylate tyrosine residues on the cytoplasmic tail of the 
IFNAR1-IFNAR2 receptor complex; and serve as recruitment sites for cytoplasmic 
STAT1 and STAT2 proteins. Upon tyrosine phosphorylation via the JAKs, STAT1 and 
STAT2 form heterodimers which are further complexed with cytoplasmic IRF9. This 
STAT1-STAT2-IRF9 complex forms the transcription factor ISGF3. 
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Activated ISGF3 translocates to the nucleus where it associates with ISRE promoter 
sequences to initiate the transcription of ISGs. Adapted from [178].
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Figure 4. Ifnb gene enhanceosome 
 The induction of Ifnb gene transcription requires the assembly, activation and 
binding of several transcription factors to specific DNA-sequences in the gene promoter 
region; as well as the assembly of mammalian architectural proteins called high mobility 
group I (HMG I) [200, 201]. Upon pathogen stimulation, the transcription factors AP-1, 
NF-κB, and the IRFs (IRF3 and/or IRF7) become active, translocate to the nucleus, and 
bind to specific positive regulation domains (PRDs): PRD IV, PRD II, and PRD –III –I; 
respectively, where along with coactivators, they initiate the transcription of the Ifnb gene 
[202]. The HMG I proteins are required for recruitment of the transcription factors to 
their respective PRDs [200]. Negative regulation domains (NRDs) are also found in the 
promoter region. Figure adapted from [201].
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Figure 5. Type I IFN positive-feedback amplification loop 
 To amplify the production of type I IFNs, IFN-β (and some IFN-α subtypes) 
employs the use of a positive feed-back mechanism in which (1) pathogen-induced IRF3 
activation leads to the initial expression of small quantities of IFN-β. (2) The secreted 
type I IFNs bind to the IFNAR heterodimeric complex of the same cell (or neighboring 
cells) ultimately activating the ISGF3 transcription complex that translocates to the 
nucleus and (4) binds to the ISRE promoter sequence of the IRF7 gene; initiating 
transcription and translation of IRF7. (5) IRF7 is phosphorylated/activated in the 
cytoplasm via kinases associated with PRR signaling pathways [203, 204], and upon 
activation translocates to the nucleus to initiate optimal transcription of IFN-β and some 
IFN-α subytypes [195]. Figure adapted from [178, 198].
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 The antiviral properties of type I IFNs are well documented and provided the 
initial evidence of the biological functions of these interferons upon pathogen 
stimulation. The antibacterial effects of type I IFNs are becoming of increased interest, 
and have proved to be more complicated. The first antibacterial effect of type I IFNs was 
documented in Chlamydia species where de la Maza et al, showed a significant decrease 
in Chlamydia replication in non-hematopoeitic cells treated with IFN-α [205]. 
Furthermore, type I IFNs were also shown to inhibit the Chlamydia growth cycle by 
inhibiting the primary differentiation of the EB to RB [206]. In addition, Devitt et al, 
showed the significant production of type I IFNs as well as inducible nitric oxide 
synthase, an enzyme required to produce the free radical nitric oxide, upon C. 
trachomatis infection [207]. Additional intracellular bacteria such as Legionella 
pneumophila possess the limited ability to replicate in macrophages dependent on 
autocrine type I IFN signaling [170]. 
V. STAT1 
 As suggested by their nomenclature, STATs possess dual roles as both signal 
transducers and transcription factors. STAT1 was the first STAT identified as a latent 
cytoplasmic factors activated by IFNs upon extracellular stimulation [208-211]. Since 
then six additional mammalian STAT proteins (STATs 1-4, 5a, 5b, and 6) have been 
identified and shown to be activated upon the ligation of specific cytokines to their 
appropriate receptors [182, 212-214]. Both type I and type II interferons are known to 
induce transcriptional responses mediated predominately by the JAK/STAT signaling 
pathway, with STAT1 playing a crucial role in both instances [169, 182]. Alternatively, 
STAT1 is among the few STATs that have been shown to become directly or indirectly 
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activated via the stimulation of other receptors that possess intrinsic receptor tyrosine 
kinase activity (i.e. growth factor receptors); independent of IFN signaling [182, 215]. 
 The basic model of activation for STAT1 and the other STAT proteins involves a 
series of three tyrosine phosphorylations via the JAKs, that ultimately result in the 
phorphorylation of a single tyrosine (Y) residue (residue Y701) [169, 182, 208, 216-218]. 
STAT1 and STAT3 have also displayed a requirement for phosphorylation of a serine 
residue 727 to achieve maximal transcriptional activity, and can occur independently of 
tyrosine phosphorylation [216, 219, 220]. STAT1 inactivation has been linked to several 
biological events including nuclear import/nuclear export signals, the upregulation and 
expression of genes encoding specific phosphatases, suppressors of cytokine signaling 
(SOCS) and more recently, acetylation via the histone acetyltransferase (HATs) CREB-
binding protein (CBP) [221-224]. In addition, studies have revealed mechanisms by 
which cytoplasmic or “latent” STAT1 proteins remain inactive and sequestered in the 
cytoplasm. Lackmann et al, showed that unphosphorylated STAT1 and STAT3 proteins 
can form dimers in the cytoplasm in association with additional factors. Furthermore, 
these unphosphorylated STAT1 dimers conform to an anti-parallel state inhibiting 
required protein-protein interactions and exposing tyrosine residues for 
dephosphorylation if necessary [182, 225-227]. 
 Upon activation and subsequent dimerization, STATs are recruited to the nucleus 
where they associate with specific DNA sequences (i.e. ISREs), and initiate the 
transcription of target genes [182, 228]. Transcriptional regulation by STAT1 is achieved 
via several mechanisms that modulate protein-protein interactions, post-translational 
modification (i.e. serine 727 phosphorylation), and the recruitment of specific co-
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activators (i.e. CBP) [217, 220, 229-231]. Interestingly, studies in human epithelial cell 
models have shown an accumulation of unphosphorylated STAT1 in the nucleus that is 
involved in upregulating, specifically, immunoregulatory genes persisting for days 
following a low-concentration of IFN-β stimulation [232]. The modulation of STAT1 
function is critical for its biological impact and is directly related to the structural 
domains of the protein (Figure 6); which is conserved among the STAT protein family.
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Figure 6. STAT1 protein structure 
 The functional activities of STAT1 and all STATs (i.e. signal transduction, 
nuclear import/export, and transcriptional activity) are directly correlated to the structural 
domains of the proteins. STAT1 protein structure (amino acids 130-712) consists of a 
transactivation domain (TAD) encompassing the Y701 phosphorylation site, and serves 
as the site for the recruitment of key coactivators that aid in efficient transcriptional 
activity. The Src-homology 2 (SH2) domain is required for the initial recruitment of 
STAT1 to the receptor-associated kinases or JAKs for initial phosphorylation, and for the 
subsequent dimerization of the STAT proteins. The DNA-binding domain (DBD) is a key 
requirement for STAT1 transcriptional activity. The amino (N)-terminal domain, linker 
domain and coiled-coil domain have been implicated in critical protein-protein 
interactions among STATs, between STATs and other co-factors, and in nuclear 
import/export; regulating activation-deactivation cycles and transcriptional activity [213]. 
Adapted from [227].
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VI. STAT1 and Pathogen-induced Immune Responses 
 STATs are implicated in a wide variety of biological occurrences including 
embryonic development in mice, the regulation of cellular growth, and the modulation of 
pathogen-induced immune responses in mice and humans [233-236]. Though STAT1 and 
STAT2 are activated upon IFN stimulation, STAT1 can be phosphorylated upon the 
initial recognition of pathogens and independent of IFN-stimulation, whereas STAT2 is 
activated predominantly by the “early” type I IFNs [216, 237]. STAT1 activation has 
been shown to mediate IFN-induced gene expression in virally stimulated macrophages 
[112]. STAT1 mutations in human and mouse models have been associated with severe 
susceptibility to Mycobacterial and viral infections which coincides with severely 
diminished innate immune responses [238, 239] and a complete lack of responsiveness to 
IFN-α and IFN-γ [239], respectively. In a Vesicular Stomatitis Virus (VSV) model, the 
STAT1-mediated induction of nuclear pore proteins has been shown to overcome the 
inhibition of proteins translocating to the nucleus as a possible antiviral strategy [240]. 
Other studies utilizing viral models such as VSV, have shown increased susceptibility 
and mortality to infection in both IFNAR -/- and STAT2 -/- [237]. However, influenza 
virus models have demonstrated a requirement for STAT1 in tissue tropism and the 
ultimate clearance of the pathogen [241, 242]. These findings highlight the overall 
importance of STAT-mediated IFN signaling in viral infections. 
 During bacterial infections the precise actions of IFNs and the STATs that 
mediate them are more complicated and tend to vary between microorganisms. Unlike 
some viral infections, STAT2 -/- and IFNAR -/- mice revealed similar mortality rates 
compared to wild-type controls upon Listeria infection [237, 243]. Though STAT1 has 
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been implicated in bacterial clearance, some studies have shown STAT1-dependent cell 
death of macrophages infected with Listeria [244]. Other groups have shown decreased 
bacterial pathology upon infection with Mycobacteria and Chlamydia species in 
epithelial cells utilizing IFNAR -/- mouse models [163, 245]. In contrast, many 
intracellular pathogens including Mycobacterium, Salmonella, and Chlamydia have been 
shown to disrupt STAT1 activity; as the host relies heavily on STAT1-mediated defenses 
to achieve optimal clearance and protective immunity [239, 246-249].
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VII. Present Studies 
 Using C.muridarum, formerly known as mouse pneumonitis strain (MoPn), and a 
murine oviduct epithelial (OE) cell infection model as a surrogate for C. trachomatis 
infection in humans, we previously showed that Chlamydia infection of OE cells results 
in the TLR-dependent synthesis of proinflammatory cytokines and chemokines including: 
CCL5, IL-6, GM-CSF, and IFN-β [155]. Subsequent studies identified TLR3 as the 
primary PRR stimulated in oviduct epithelial cells resulting in the Chlamydia-induced 
synthesis of IFN-β [155, 250, 251]. However, our data revealed that the OE cells were 
still capable of producing residual amounts of IFN-β during Chlamydia infection, despite 
the absence of a functional TLR3. The ability of the OE cells to secrete residual amounts 
of Chlamydia-induced IFN-β in the absence of TLR3 implicates the existence of 
additional pathways that may be involved in this response. Others have demonstrated the 
existence of multiple pathways that Chlamydia uses to induce type I IFN synthesis in 
various cell types including the MYD88-dependent pathways observed in peritoneal 
macrophages [160], pathways that include signaling through the “rat sarcoma” (RAS) 
signaling adaptor molecule cytosolic phospholipase A2 (cPLA2) in mouse embryo 
fibroblasts [252], and TLR-independent pathways that signal via NOD 1 and stimulator 
of IFN gene (STING) protein [253]. The multitude of pathways induced by Chlamydia to 
synthesize type I IFN underscores the redundancy in the mechanisms of immune 
response to infection, and highlights the importance of type I IFNs in Chlamydia 
pathogenesis. 
 The investigation into the role of STAT1 in response to Chlamydia-induced type I 
IFN synthesis in HeLa 229 cells demonstrated a robust IFN-β-dependent upregulation 
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and increased activation of components of the JAK/STAT signaling pathway that 
appeared to be essential for restricting pathogen replication [254]. In this study, we 
investigate the role of STAT1 and JAK/STAT signaling in the Chlamydia-induced IFN-β 
response in OE cells, to ascertain whether JAK/STAT signaling pathways contribute to 
IFN-β synthesis in OE cells as was observed in the HeLa 229 cells. Based on our 
previous observations that C. muridarum-induced IFN-β synthesis is largely TLR3-
dependent in OE cells, we hypothesize that STAT1 is upregulated and activated 
subsequent to the TLR3-dependent response in OE cells, in order to sustain and amplify 
the type I interferon response throughout the course of infection. We also hypothesize 
that JAK/STAT signaling possibly serves as a compensatory mechanism for Chlamydia-
induced IFN-β production in the absence of TLR3.  
 Herein, we show that STAT1 expression and activation is indeed upregulated in 
response to C. muridarum infection in OE cells, and we show that STAT1 is critical for 
IFN-β production at late stages of infection. We demonstrate that TLR3-deficeincy 
diminishes the expression and activation of STAT1 in infected OE cells during late stage 
infection, suggesting a dependence on the initial TLR3-dependent production of IFN-β. 
We also demonstrate that STAT1 may be involved in differentially modulating 
Chlamydia-induced mRNA expression of key components of the type I interferon 
signaling pathway, as well as, type I interferons (IFNβ/α) during early and/or late stages 
of infection. Our studies show that STAT1 plays a critical role in mediating the 
modulation of the innate inflammatory immune response in oviduct epithelial cells during 
late stage Chlamydia infections; specifically in amplifying type I interferon signaling; 
and regulating type I interferon production.
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MATERIALS AND METHODS 
I. Mice 
 C57BL/6 (control) and C57BL/6 (STAT1-deficient) matched female mice were a 
gift from Dr. Akira Moh and Dr. Xin-Yuan Fu at Indiana University School of Medicine, 
Department of Microbiology and Immunology. The mice were immediately sacrificed 
upon receipt and primary oviduct epithelial cells harvested from these mice were used for 
experiments in this study. The Indiana University Institutional Animal Care and 
Utilization Committee approved all experimental protocols. 
II. Reagents 
 Recombinant murine IFN-γ was purchased from PeproTech (Rocky Hill, NJ). The 
lyophilized IFN-γ was suspended in PBS supplemented with 0.1% bovine serum albumin 
(BSA) and frozen at -20°C until use. Immediately before use, recombinant murine IFN-γ 
was thawed and diluted to10 ng/ml in fresh epithelial cell media. Recombinant murine 
IFN-β was purchased from R&D Systems (Minneapolis, MN). The recombinant murine 
IFN-β was reconstituted, stored, and used as previously described [255]. Purified anti-
mouse type I interferon-alpha receptor 1 (IFNAR1) neutralizing antibody against subunit 
1 of the heterodimeric type I interferon receptor, and the mouse IgG1 isotype control 
were purchased from Biolegend (San Diego, CA). The neutralizing antibody and isotype 
control were stored according to manufacturers’ recommendations. IFNAR neutralizing 
antibody and mouse isotype control were diluted to two times a working concentration of 
4.61 ng/ml in fresh epithelial cell media for neutralization experiments. Rat monoclonal 
neutralizing antibody against murine IFN-β was purchased from Abcam, Inc. 
(Cambridge, MA). The neutralizing antibody was aliquoted and frozen at -80°C until use. 
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Rat monoclonal neutralizing antibody against murine IFN-β was thawed and diluted to 
two times a working concentration of 3.6 ng/ml in fresh epithelial cell media immediately 
before use. The isotype control antibody, as described above, was used at a similar 
concentration as the IFN-β neutralization antibody as a negative control. Fludarabine, a 
nucleoside analog and potent inhibitor of STAT1 [256] was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA) and used at 1 µg/ml for inhibitor experiments. 
III. BMDM Isolation 
 The derivation and maintenance of BMDMs from C57BL/6 wild-type (WT) mice 
and C57BL/6 STAT1 (-/-) was achieved by carefully removing the femurs, tibias, and 
fibulas from the sacrificed mice followed by sterilization with 70% ethanol and repeated 
washes with complete RPMI media obtained from Sigma (St. Louis, MO) supplemented 
with 10% characterized fetal bovine serum (FBS) purchased from HyClone (Logan, UT), 
2mM L-alanyl-L-glutamine (Glutamax I) purchased from Invitrogen (Grand Island, NY), 
1 ml mercaptoethanol (Invitrogen) and 50 µg/ml of gentamicin (Sigma). Next, the 
epiphyses and diaphysis were cut from the femurs and tibias, exposing the marrow 
cavity. Using a 27 gauge needle, 3 ml of ice cold complete RPMI media was injected into 
the cavity to recover bone marrow into sterile Petri plates. The removed epiphyses and 
diaphysis were crushed in .5 ml of ice cold complete RPMI media to obtain residual 
marrow. Bone marrow red blood cells were lysed by adding 3.5 ml of 
ammonia/chloride/potassium (150 mM NH4Cl, 1 mM KHCO3, and 0.001 mM EDTA 
buffer) lysing buffer (Invitrogen) for 3 minutes at room temperature. The lysate was 
strained through a 40 µm screen column and centrifuged at 1200 rpm for 5 minutes. The 
pellet was then washed with and cells resuspended in RPMI media supplemented with 
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10% characterized fetal clone serum (FC3) purchased from HyClone (Logan, UT), 
Glutamax I (Invitrogen), 1 ml mercaptoethanol (Invitrogen) per 500 ml of RPMI media 
and 50 µg/ml of gentamicin (Sigma). The cells were plated at a concentration of 2 x 10
6 
cells/ml of the above RPMI media. The cells were further supplemented with an equal 
volume of RPMI media containing 40 ng/ml GM-CSF, and plated in a 24-well culture 
plate until 70-80% confluency, at which time cells were passaged until needed. 
IV. Cells and bacteria 
 The derivation and maintenance of cloned oviduct epithelial cell lines OE129 
TLR3 (-/-) and OE129 WT has previously been described [44, 155, 250], and a new 
cloned epithelial cell line described in this report, designated OEB6 STAT1 (-/-) and 
OEB6 WT, were derived using a similar method. Reproductive tract tissues from 
C57BL/6 (control) and C57BL/6 (STAT1-deficient) female mice, encompassing a small 
cuff of the ovary, were harvested. Luminal epithelial cells were released with a 
pancreatin-hyaluronidase-collegenase mixture. The resulting epithelial cells were 
expanded in vitro and cloned by limiting dilution. Resulting clones were screened and 
epithelial cell lineage confirmed by a previously described method [155]. Selected clones 
were expanded and designated OEB6 STAT1 (-/-) and OEB6 WT from STAT1-deficient 
and WT, respectively. The upper reproductive tract epithelial cells were grown at 37°C in 
a 5% CO2 humidified incubator and maintained in epithelial media: 1:1 DMEM:F12K 
(Sigma), supplemented with 10% characterized FBS (HyClone), 2mM L-alanyl-L-
glutamine (Glutamax I; Invitrogen), 5 µg of bovine insulin/ml, and 12.5 ng/ml of 
recombinant human fibroblast growth factor-7 (keratinocyte growth factor; Sigma) as 
previously described [44, 155, 251]. WT and STAT1 (-/-) BMDMs were grown at 37°C 
34 
in a 5% CO2 humidified incubator and maintained in RPMI media supplemented with 
10% FC3 (HyClone), Glutamax I (Invitrogen), 1 ml mercaptoethanol (Invitrogen) per 
500 ml of RPMI media and 50 mg/ml of gentamicin (Sigma).  
 Mycoplasma-free C. muridarum, previously known as C. trachomatis strain 
mouse pneumonitis (MoPn), were given to us as stocks that came from the Johnson lab 
originally purchased from American Type Culture Collection (Manassas, VA); and 
grown and titered in McCoy cells as previously described [44, 257]. 
V. RNA interference: generation of STAT1-knockdown OEs 
 Small interfering RNA (siRNA) control plasmid (psiLucGL3) and mouse STAT1 
plasmid (psimSTAT1) were purchased from Invivogen (San Diego, CA). Both plasmids 
were used at a concentration of 1 µg and transformed into competent E. coli GT116 cells 
(Invitrogen) using the standard transformation conditions and according to the 
manufacturer’s protocol. The transformants were grown on agar plates supplemented 
with 25 µg/ml of Zeocin (Invivogen); to which both plasmids were designed to confer 
resistance (Figure 7), and subsequent colonies selected and amplified per manufacturer’s 
protocol using the Quick Plasmid Midi Prep Kit purchased from Qiagen (Valencia, CA). 
Post-amplification, the plasmid DNA concentrations were quantified via 
spectrophotometric analysis using the Nanodrop 2000 (Thermo Scientific; Wilmington, 
DE), and 10 µg of each plasmid was transfected per manufacturer’s protocol into OE129 
WT cells using the Amaxa Nucleofector Kit R purchased from Lonza (Basel, 
Switzerland). Cells were designated OE129 WT (psimSTAT1) and OE129 WT 
(psiLucGL3), and maintained in epithelial media at 37°C in a 5% CO2 humidified 
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incubator until 70% confluent. Transfection efficiencies were determined by flow 
cytometric analysis for green fluorescent protein (GFP)-labeled cells. 
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Figure 7. Basic plasmid map of psimSTAT1 
 The basic backbone of the ready-made plasmid used for small interfering Stat1 
mRNA in OE cells is composed of Zeocin (Zeo)-resistant DNA sequences, as well as 
GFP; and expression is driven by the 7SK and Cytomegalovirus (CMV) promoters. The 
psiLucGL3 control plasmid was composed of similar DNA sequences and expression 
driven under similar promoters. Figure adapted from Invivogen; at www.invivogen.com. 
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VI. Chlamydia muridarum infections 
 All cells were plated in 24-well tissue culture plates and used when 70-80% 
confluent. For all experiments, the cells were infected with 10 IFUs of C. muridarum/cell 
in 750 µl of epithelial cell culture medium. The plates were centrifuged at 1200 rpm (200 
× g) in a table-top centrifuge for 1 hour then incubated at 37°C in a 5% CO2 humidified 
incubator without subsequent change of medium for 24 hours. Mock-infected and 
cytokine and/or neutralizing antibody-treated only wells received an equivalent volume 
of epithelial cell culture medium lacking C. muridarum. 
VII. Enzyme-linked immunosorbent assay (ELISA) determination of cytokine 
production 
 OE129 WT, OE129 TLR3 (-/-), OEB6 WT, OEB6 STAT1 (-/-), WT BMDMs, 
STAT1 (-/-) BMDMs, or OE129 WT and TLR3 (-/-) transfected with either 
(psimSTAT1) and/or the control plasmid; were plated in 24-well tissue culture plates to 
confluency. The cells were either infected with 10 IFU of C. muridarum/ cell and/or 
treated with the appropriate cytokine or antibody at the concentrations specified in the 
text. Supernatants were harvested at 24 hour or the indicated timepoints, and analyzed for 
cytokine content using ELISAs for IFN-β and/or IL-6, as previously described [155]. All 
standards and experimental samples were analyzed in triplicate. The lower range of assay 
sensitivity for individual cytokines was 50 pg/ml and 10 pg/ml for IL-6 and IFN-β; 
respectively. Optical densities taken at 450 nm for quantification were measured using a 
microplate reader (Bio-Rad; Hercules, CA).
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VIII. RT-PCR 
 Total RNA was isolated from mock-infected, IFN-γ-treated and C. muridarum-
infected OE129 WT, OE129 TLR3 (-/-), OEB6 WT, and OEB6 STAT1 (-/-) cells using 
the RNeasy kit (Qiagen). During purification, all RNA samples were treated with RNase-
free DNase I (Qiagen) to remove genomic-DNA contamination and were quantified by 
the Nanodrop 2000 (Thermo Scientific). Total RNA was then reverse transcribed into 
cDNA using the iScript cDNA synthesis kit (Bio-Rad), according to the manufacturer’s 
protocol, using standard cycling conditions. Specific primer pairs for Stat1 and β-actin 
were used to amplify 1-2 µg of cDNA. Optimized primer pairs were designed by using 
the Primer 3 design tool [258]. The specific primer pairs (Invitrogen) used for Stat1 and 
β-actin are as follows: sense 5´ TCA GAA ATC CGC CTG TCT CT 3´, antisense 5´ 
TCA TTT CAT TTT GGC ATG GA 3´ (Stat1) and sense 5´ TAC GTA GCC ATC CAG 
GCT GT 3´, antisense 5´ AAG GAA GGC TGG AAA AGA GC 3´ (β-actin), 
respectively. Using 1-2 µg of cDNA as the template for each reaction, RT-PCR was 
accomplished by using iScript RT-PCR kit (Bio-Rad) as described in the manufacturers’ 
protocol. The cycling conditions were as follows: 2 min of initial denaturation at 95°C, 
followed by 35 cycles of 30 s at 95°C, 15 s at 60°C, and 30 s at 68°C. During the 35
th
 
cycle, the 72°C extension was 2 min to complete the RT-PCR. Reactions were also 
amplified in the absence of reverse transcriptase as negative controls. 
IX. Western blotting 
 OE129 WT, OE129 TLR3 (-/-), OEB6 WT, and OEB6 STAT1 (-/-) cells were 
plated in 24-well tissue culture plates to confluency. Subsequently, these cells were either 
mock-infected, IFN-γ-treated, or C. muridarum-infected for indicated time-points. After 
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removal of the cell supernatants, the cells were gently washed with PBS. Soluble proteins 
were then extracted with a lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM 
NaCl, 1% Triton X-100, 0.1% SDS purchased from Imgenex (San Diego, CA), and a 
mixture of protease inhibitor cocktail at 1 µl/ml (Sigma); incubated on ice for 30 minutes. 
Cell lysates were clarified by centrifugation at 14,000 rpm (2400 × g) and proteins were 
quantified and separated by SDS-PAGE as previously described [251]. After proteins 
were transferred to nitrocellulose transfer membranes (Bio-Rad), the transfer membranes 
were blocked according to the manufacturer’s protocol with a protein-free Tris-buffered 
saline (pH 7.4) containing 0.05% Tween-20 blocking buffer purchased from Pierce 
(Rockland, IL). The proteins were stained by immunoblotting with either a 1:2000 
dilution of a murine antibody against total STAT1, a 1:2500 dilution of phosphorylation-
specific (pY701) STAT1 antibody (both obtained from BD Bioscience (San Jose, CA)), 
or a 1:3000 dilution of phosphorylation-specific (Serine residue 396) IRF3 antibody 
purchased from Cell Signaling (Boston, MA). Protein-antibody complexes were detected 
by secondary blotting with a 1:10,000 dilution of horseradish peroxidase-conjugated goat 
anti-mouse polyclonal antibody (Pierce). Proteins were visualized using the ECL western 
blotting substrate (Pierce) as described in the manufacturer’s protocol. 
X. Recombinant cytokine treatment 
 To serve as a positive control for the induction of STAT1 protein activation and 
STAT1 protein/Stat1 gene expression, recombinant murine IFN-γ was added directly to 
the media of OE129 WT, OE129 TLR3(-/-), OEB6 WT, and OEB6 STAT1(-/-) cells at 
10 ng/ml for 4-6 hours (18-20 h post mock-infection). Recombinant IFN-β treatment was 
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achieved by adding recombinant IFN-β directly to the medium of the cells at 10 U/ml for 
4 hours (20 h post mock-infection) for most experiments. 
XI. Neutralization Experiments 
 For IFNAR neutralization experiments, the OE cells (OE129 WT, TLR3 -/-, 
STAT1 -/-) were either infected with C. muridarum or treated with IFN-β, and the 
IFNAR activity blocked with a neutralizing antibody against murine IFNAR1 at both 
early-stage infection (6hr) and late-stage infection (16hr). For 6 hour infections, cells 
were infected with C. muridarum and treated with IFNAR neutralizing antibody added to 
the cell supernatants at time 0 (T0) at the indicated concentration for the duration of the 
infection. The cells treated with recombinant IFN-β only received equal volumes of 
epithelial media, incubated at 37°C for 1 hour; after which, recombinant IFN-β was 
added to the cell supernatants at the indicated concentration and cell lysates and 
supernatants were harvested 5 hours later (6 hour infection). The cells treated with 
recombinant IFN-β and IFNAR neutralizing antibody received each treatment at the 
indicated concentrations, simultaneously, at T0 and cell lysates and supernatants 
harvested at 6 hours. Normal mouse IgG1 isotype control antibody was used in a similar 
fashion in conjunction with recombinant IFN-β to serve as a negative control. For 16 
hour infections, cells were infected with C. muridarum and treated with IFNAR 
neutralizing antibody added to the cell supernatants 11 hours post-infection time 11 (T11) 
at the indicated concentration; and cell lysates and supernatants were harvested 5 hours 
later (16 hour infection). The cells treated with recombinant IFN-β only received equal 
volumes of epithelial media, incubated at 37°C for 1 hour; after which, recombinant IFN-
β was added to the cell supernatants at the indicated concentration for 9 hours. After the 9 
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hour incubation, the epithelial media was removed and replaced with fresh media. The 
cells incubated at 37°C for 1 hour; after which, recombinant IFN-β was added to the cell 
supernatants at the indicated concentration and cell lysates and supernatants were 
harvested 5 hours later (16 hour infection). The cells treated with recombinant IFN-β and 
IFNAR neutralizing antibody received equal volumes of epithelial media, incubated at 
37°C for 1 hour; after which, recombinant IFN-β was added to the cell supernatants at the 
indicated concentration for 9 hours. After the 9 hour incubation, the epithelial media was 
refreshed and the cells incubated at 37°C for 1 hour; after which, IFNAR neutralizing 
antibody was added to the cell supernatants at the indicated concentrations and incubated 
at 37°C for 1 additional hour. Following the 1 hour incubation of the IFNAR neutralizing 
antibody, recombinant IFN-β was added to the cell supernatants at the indicated 
concentration and cell lysates and supernatants were harvested 4 hours later (16 hour 
infection). Normal mouse IgG1 isotype control antibody was used in a similar fashion in 
conjunction with recombinant IFN-β to serve as a negative control. 
 IFNAR neutralization experiments were also performed for OE129 WT cells 
infected with C. muridarum for 24 hours and treated with IFNAR neutralizing antibody at 
the indicated concentrations; at early (T0) versus late (T16) points in infection. The cells 
were mock-infected or infected with C. muridarum and supernatants harvested at 24. 
Cells were also Chlamydia-infected and treated with IFNAR neutralizing antibody or the 
normal mouse isotype control at T0 and supernatants collected at 24 hours. Additionally, 
the WT cells were Chlamydia-infected and treated with IFNAR neutralizing antibody or 
the normal mouse isotype control at T0 and supernatants collected at 16 hours; followed 
by the addition of fresh epithelial cell media and treatment with IFNAR neutralizing 
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antibody or the normal mouse isotype control at T16 and cell supernatants collected 8 
hours later (24 hour infection). All supernatants collected were analyzed for IFN-β 
production via ELISA. 
 For IFN-β neutralization experiments OE129 WT cells were either infected with 
C. muridarum or treated with IFN-β and the IFN-β activity blocked with a monoclonal 
neutralizing antibody against murine IFN-β at both early-stage infection (6hr) and late-
stage infection (16hr). For 6 hour infections, OE129 WT cells were infected with C. 
muridarum and treated with IFN-β neutralizing antibody added to the cell supernatants 1 
hour post-infection at time 1 (T1) at the indicated concentration for the duration of the 
infection. Next, recombinant IFN-β and the IFN-β neutralizing antibody were allowed to 
incubate together at the indicated concentrations for 1 hour at room temperature in order 
to form specific antigen-antibody (Ag-Ab) complexes before being added to the culture 
media. Cell lysates and supernatants were harvested 5 hours later (6 hour infection). 
Normal mouse IgG1 isotype control antibody was used in a similar fashion in 
conjunction with recombinant IFN-β to serve as a negative control. For 16 hour 
infections, OE129 WT cells were infected with C. muridarum and treated with IFN-β 
neutralizing antibody added to the cell supernatants 1 hour post-infection (T1) at the 
indicated concentration and allowed to incubate for 6 hours; after which, the epithelial 
media was removed and replaced with fresh media. The cells incubated at 37°C for 1 
hour. At 8 hours post-infection, IFN-β neutralizing antibody was added to the supernatant 
and cell lysates and supernatants were harvested 8 hours later (16 hour infection). 
Recombinant IFN-β and the IFN-β neutralizing antibody were allowed to form Ag-Ab 
complexes as previously described and added to the cells supernatants at 8 hours post-
43 
incubation at 37°C; cell lysates and supernatants were harvested 8 hours later (16 hour 
infection). Normal mouse IgG1 isotype control antibody was used in a similar fashion in 
conjunction with recombinant IFN-β to serve as a negative control. The cells treated with 
recombinant IFN-β only were treated in a similar manner as in the IFNAR neutralization 
experiments for both 6 and 16 hour time-points. 
XII. Quantitative real-time PCR 
 Total RNA was purified from OE129 WT, OE129 TLR3 (-/-), and OEB6 STAT1 
(-/-) cells using the RNeasy Plus kit (Qiagen). Specialized spin columns provided in the 
kit were used for all samples during purification to ensure the removal of genomic-DNA 
contamination; however, each sample was subjected to an addition on-column DNase I 
treatment to ensure complete removal of cellular and bacterial DNA. The purified RNA 
was quantified by spectrophotometric analysis. Total RNA was reverse transcribed into 
cDNA using the iScript cDNA synthesis kit (Bio-Rad) according to the manufacturer’s 
protocol and using standard cycling conditions. Optimized primer pairs were designed 
from published data and reputable databases [259, 260]. The cDNA product was diluted 
1:20, and the Ifnb-specific, Irf3-specific, Irf7-specific, Stat1-specific, Stat2-specific, 
Ifna4-specific, Ifna2-specific, and β-actin-specific control primers (Table I) were adjusted 
to 2 pmol/µl working stock. Quantitative real time PCR was conducted with the diluted 
cDNA and primers as per the protocol outlined in the iScript One-Step RT-PCR with 
SYBR Green kit (Bio-Rad), and as described [251]. Dissociation curves were recorded 
after each run to ensure primer specificity. 
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Table 1. Primers used in quantitative real-time PCR experiments. All primers are listed 
in the 5ʹ to 3ʹ orientation. Control reactions were set up with the β-actin primers as the 
loading control. 
XIII. Immunofluorescent Staining 
 OEB6 WT, and OE STAT1 (-/-) cells were cultured in a 24-well tissue culture 
plate and allowed to grow to 70% confluence. The cells were then mock-infected or 
infected with C. muridarum as previously described. At 24 hours post infection, the 
infected cells were then fixed with 200 µl of methanol and incubate at room temperature 
for 10 minutes. The fixed cells were stained with a murine anti-Chlamydia LPS antibody, 
provided by Dr. Wilbert J. Newhall [261], diluted 1:500 in PBS and incubated for 1 hour 
at room temperature. The stained cells were washed 3 times with PBS. Detection was 
Primer 
Name 
Sense Primer Antisense Primer Product 
Size 
(bp) 
Ifnb 
   
Ifna2 
   
Ifna4 
   
Stat1 
   
Stat2 
   
Irf7 
   
Irf3 
   
β-actin 
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accomplished with a secondary stain of fluorescein isothiocyanate-conjugated (FITC) 
goat anti-mouse IgG antibody (Rockland) diluted 1:50 in PBS. 
XIV. STAT1 Inhibitor Experiment 
 In 24-well tissue culture plates, OE129 WT cells were mock-infected, infected 
with C. muridarum, or C.muridarum-infected with fludarabine-treatment at 4-, 6-, or 16-
hours post-infection at a concentration of 1 µg/ml and infections carried out to the 24-
hour time-point. The cell supernatants were harvested and analyzed for IFN-β production. 
XV. Statistical Analysis 
 Data are expressed as means ± SD. All experiments were repeated at least three 
times, and statistical significance determined using Student’s two-tailed t test. Values of p 
< 0.05 were considered statistically significant.
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RESULTS 
CHAPTER I. ESTABLISH A ROLE FOR STAT1 IN REGULATING 
CHLAMYDIA-INDUCED TYPE I IFN RESPONSES IN OE CELLS 
A. C. muridarum induces increased STAT1 protein activation/expression and Stat1 
gene expression 
 Reports have shown that C. trachomatis induced significantly increased STAT1 
protein activation and expression in HeLa 229 cells, albeit in an IFN-β-dependent manner 
[254]. In an effort to identify a role for STAT1, in the context of type I interferon 
synthesis and signaling in C. muridarum-induced OE cells, we first examined Stat1 gene 
expression and STAT1 protein activation in wild-type OE cells via RT-PCR and western 
blot analysis, respectively. We utilized two wild-type OE cell lines designated OE129 
WT and OEB6 WT that were either mock-infected, treated with IFN-γ (10 ng/ml), or 
infected with 10 IFU/cell of C. muridarum. Representative data was taken from the 24 
hour time point whereby we assessed Stat1 expression and STAT1 expression/activation 
by RT-PCR and by western blot. C. muridarum-infection significantly increased Stat1 
mRNA levels (as compared to mock-infected controls) in both wild-type OE cell lines 
(Figure 8). Interferon-gamma is a well-known inducer of Stat1 expression and STAT1 
activation [182, 216] and C. muridarum-induced Stat1 mRNA expression at a level 
comparable to that of the IFN-γ-treated controls (Figure 8). Increased gene expression 
does not necessarily correspond to increased protein expression or activity. We 
performed western blot analysis to examine total STAT1 protein expression and 
activation (phosphorylation) upon C. muridarum infection. C. muridarum-infected wild-
type OE cells expressed significantly greater total STAT1 and increased STAT1 
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phosphorylation as compared to mock-infected controls (Figure 9). These increases in 
total STAT1 protein expression and STAT1 activation were also comparable to those of 
the IFN-γ-treated controls (Figure 9). Collectively, the data indicate that C. muridarum 
induces Stat1/STAT1 expression and STAT1 activation in OE cells in a manner similar 
to that which was observed in studies describing STAT1 activation in HeLa 229 cells 
infected with C. trachomatis [254]. 
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Figure 8. C. muridarum infection increases Stat1 mRNA message relative to mock-
infected controls in WT oviduct epithelial cells 
 Semi-quantitative RT-PCR was performed using 1 µg of cDNA reverse 
transcribed from RNA isolated from WT OEs that were mock-infected, infected with C. 
muridarum at 10 multiplicity of infection (MOI) for 24 hours, or treated with 10 ng/ml of 
IFN-γ for 4-5 hours. Stat1 primers were used to amplify Stat1 mRNA message; and β-
actin primes were used to amplify β-actin mRNA message as a loading control.
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Figure 9. C. muridarum infection increases STAT1 protein expression and activation 
relative to mock-infected controls in WT OEs 
 Twenty microgram of protein in whole cell lysates from: (A.) OE129 WT or (B.) 
B6 WT OEs that were mock-infected, infected with C. muridarum at 10 MOI for 24 
hours, or treated with 10 ng/ml of IFN-γ for 4-5 hours; were separated on a 10% 
polyacrylamide gel. Proteins were transferred to a nitrocellulose membrane and probed 
with antibody to phosphorylated STAT1 (tyrosine residue 701), total STAT1 and β-actin. 
β-actin served as a loading control. The results shown are representative of three 
independent experiments. Densitometric analysis of total STAT1 expression and STAT1 
phosphorylation are shown for each cell line relative to the β-actin control (indicated as 
β-act in the graphs), and C. muridarum-infection indicated by MoPn. 
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B. STAT1 is required for C. muridarum-induced IFN-β production during the late 
stage of infection 
 We described an upregulation in Stat1/STAT1 expression and STAT1 activation 
in response to C. muridarum infection of wild-type OE cells that were harvested at 24hr 
post-infection (PI) in the previous data set. Therefore, we sought to determine if STAT1 
played a functional role in Chlamydia-induced IFN-β synthesis. To ascertain whether the 
increased Stat1 gene expression and STAT1 protein activation contributed to the C. 
muridarum-induced IFN-β response in OE cells, OEB6 WT and OE STAT1 (-/-) cells 
derived from C57BL/6 control and STAT1-deficient mice respectively, were infected 
with C. muridarum, and the amount of IFN-β secreted in supernatants at 24 hr PI was 
measured (Figure 10). As shown, IFN-β production was significantly increased upon 
Chlamydia infection in B6 WT cells (compared to mock-infected cells); however, the 
amount of C. muridarum induced IFN-β synthesis at 24 hr PI in the OE STAT1 (-/-) cells 
was substantially reduced and was not significantly different than that of mock-infected 
controls. We observed similar results using BMDMs that were isolated from wild-type 
and STAT1-deficient mice and were infected with 10 IFU/cell C. muridarum (data not 
shown).
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Figure 10. C. muridarum-induced IFN-β production is diminished in STAT1-
deficient OEs 
 OEB6 WT cells and STAT1-deficient (STAT1-/-) OE cells were mock-infected 
and/or infected with 10 MOI of C. muridarum (denoted as MoPn), for 24 hours. ELISA 
was used to measure infection-induced IFN-β secreted into the supernatants of mock-
infected and C. muridarum-infected: (A.) B6 WT cells, and (B.) STAT1 (-/-) cells. The 
data represent mean ± SD and are representative of three different experiments conducted 
in triplicate. Significance was determined using Student’s T test; **=p value <0.005 for 
mock-infected vs MoPn-infected; NS=not significant. 
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C. STAT1 is critical for regulating in vitro C. muridarum replication/growth in OE 
cells 
 We have provided data that highlights STAT1 as a critical mediator in the 
synthesis of type I interferons (IFN-β) in C. muridarum-infected oviduct epithelial cells; 
particularly, in the secretion of IFN-β at late stages of infection and in accordance with 
previous studies implicating a TLR3-dependent IFN-β response in these cells. In 
addition, we have provided both in vitro and in vivo evidence implicating the TLR3-
dependent IFN-β response in restricting C. muridarum growth and/or replication [250, 
255]. Our data in those studies demonstrate substantially increased Chlamydia replication 
in TLR3-deficient mice and OE cells that likely reflects the significant decrease in the 
amount of IFN-β produced when compared to wild-type mice and OE cells. Therefore, 
we wondered if STAT1 would have a functional role in restricting C. muridarum 
replication in OE cells. To indirectly assess the requirement for STAT1 in Chlamydia-
induced IFN-β production we observed the in vitro effects of STAT1-deficiency on C. 
muridarum growth and replication in OE cells. Wild-type and STAT1-deficient OE cells 
were mock-infected or infected with 10 MOI C. muridarum for 24 hours followed by 
methanol fixation, and the detection of viable Chlamydia IFUs with a Chlamydia-specific 
antibody against LPS. As shown, Chlamydia IBs were detected in many of the C. 
muridarum-infected WT OEs as small round inclusions within the cell compared to 
mock-infected WT controls (Figure 11). However, the STAT1-deficient OE cells 
displayed aberrantly shaped Chlamydia IBs that appeared to span the entire area of the 
cells and were detectable in most of the cells compared to WT OEs (Figure 11); 
suggesting that STAT1 plays a critical role in restricting C. muridarum growth and 
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further supporting our observations that STAT1 is a key mediator in C. muridarum-
induced type I IFN production. 
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Figure 11. C. muridarum-infected STAT1-deficient OE cells display aberrantly 
shaped Chlamydia inclusion-forming units; implicating uncontrolled C. muridarm 
replication 
 OE129 WT and OE STAT1 (-/-) cells were mock-infected, or infected with 10 
MOI of C. muridarum (MoPn) for 24 hours. All cells were stained with a genus-specific 
anti-LPS antibody, and counterstained with a FITC-labeled anti-mouse IgG antibody for 
detection of Chlamydia inclusion bodies (IBs) via fluorescent microscopy. Note that OE 
129 WT cells were used as the control instead of OE B6 WT cells due to delayed cellular 
growth rates and faster Chlamydia clearance rates in the OE B6 WT compared to the OE 
129 WT cells. Original magnification was at 100X. 
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D. STAT1 is critical for up-regulating Ifnb transcription during late-stage C. 
muridarum infection 
 Our previous data reveals that STAT1 plays a role in Chlamydia-induced IFN-β 
production in OE cells. These data were analyzed at 24 hours post-infection; 
representative of late-stage Chlamydia-infection. We sought to determine if STAT1 
would also play a role in early-stage Chlamydia-induced IFN-β production in OE cells. 
To address the role of STAT1 in sustaining and amplifying Chlamydia-induced type I 
IFN production in OE cells and to delineate its role as either an early-stage or late-stage 
factor in the synthesis of type I IFNs, we infected wild-type, STAT1-deficient, and 
TLR3-deficient OE cells with C. muridarum, and isolated total cell RNA at either 6 hr 
(early-stage) or 16 hr (late-stage) time points. Quantitative real-time PCR was used to 
analyze and compare the subsequent effects on gene transcription of Ifnb and several 
signaling components that comprise the type I IFN signaling pathway including Stat1, 
Stat2, and Irf7 [262]. C. muridarum induced Ifnb gene expression in both the OE129 WT 
and TLR3 (-/-) cells at 6 hr PI (Figure 12), and this induction was significantly increased 
in both cell lines at the 16 hr time-point (Figure 13). The 10-fold higher induction of the 
Ifnb gene at 16 hr PI in the OE129 WT cells was substantially greater than that of the 
TLR3-deficient cells (2-fold) (Figure 13), which corroborates our previous studies 
describing the importance of TLR3 in the Chlamydia induced synthesis  of IFN-β in OE 
cells [250]. However, although STAT1-deficient OE cells exhibited a >2-fold induction 
in the expression of the Ifnb gene in response to C. muridarum infection at 6 hr PI, 
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these cells exhibited no further induction at the 16 hr time-point (Figure 14); 
corroborating the IFN-β protein data (Figure 10), and suggesting a critical role for 
STAT1 in upregulating IFN-β synthesis at late times during infection.
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Figure 12. C. muridarum-induced Ifnb gene expression is induced to similar levels 
early in infection in both WT and TLR3-deficient OEs 
 Quantitative real-time PCR was performed using 1 µg of cDNA reverse 
transcribed from RNA isolated from OE129 WT and OE TLR3 (-/-) cells that were either 
mock-infected or infected with 10 MOI of C. muridarum (denoted as MoPn) for 6 hours. 
IFN-β primers were used to amplify Ifnb message mRNA. Control reactions were set up 
with β-actin primers to ensure equal loading of mRNA. The results are presented as mean 
fold change ± SD; and are representative data from one of three individual experiments 
conducted in duplicate.
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Figure 13. C. muridarum-induced Ifnb gene expression substantially reduced in 
TLR3-deficient OEs at 16 hr post infection 
 Quantitative real-time PCR was performed using 1 µg of cDNA reverse 
transcribed from RNA isolated from OE129 WT and OE TLR3 (-/-) cells that were either 
mock-infected, or infected with 10 MOI of C. muridarum (denoted as MoPn) for 16 
hours. IFN-β primers were used to amplify Ifnb message mRNA. Control reactions were 
set up with β-actin primers to ensure equal loading of RNA. The results are presented as 
mean fold change ± SD; and are representative data from one of three individual 
experiments conducted in duplicate.
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Figure 14. STAT1 is indispensable for effective Chlamydia-induced Ifnb gene 
induction in OE cells 
 Quantitative real-time PCR was performed using 1 µg of cDNA reverse 
transcribed from RNA isolated from STAT1-deficient (-/-) OE cells that were either 
mock-infected, or infected with 10 MOI of C. muridarum (denoted as MoPn) for 6 hours 
(white bars) or 16 hours (black bars). IFN-β primers were used to amplify Ifnb message 
mRNA. Control reactions were set up with β-actin primers to ensure equal loading of 
RNA. The results are presented as mean fold change ± SD; and are representative data 
from one of three individual experiments conducted in duplicate. Because the represented 
cell line in this figure and cell lines from the previous figures (Figure 12 and Figure 13) 
were analyzed on the same 96-well plate for each time point, we will refer to Figures 12 
and 13 to compare Ifnb mRNA levels of the WT control cell line. Again, OE 129 WT 
cells were used as the WT control instead of OE B6 WT cells due to delayed cellular 
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growth rates and faster Chlamydia clearance rates in the OE B6 WT compared to the OE 
129 WT cells. 
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 We next examined the Chlamydia-mediated gene induction of signaling mediators 
found within the type I IFN signaling pathway. As shown, both Stat2 and Irf7 genes were 
induced at similar levels, for both time-points, in the wild-type and TLR3-deficient OE 
cells (Figure 15 B and Figure 15 C). This data suggests that the type I IFN signaling 
pathway is intact and induced at similar levels, despite the substantial difference in IFN-β 
synthesis (Figure 13). OE cells deficient in STAT1 showed minimal upregualtion in 
either Stat2 or Irf7 (Figure 15 B and Figure 15 C); implicating a requirement for STAT1 
in the inductions of genes found in the type I IFN signaling pathway. Interestingly, C. 
muridarum mediated Stat1 gene induction at 16 hr PI was substantially lower in the 
TLR3-deficient cells than the wild type OE cells (Figure 15 A), despite almost equal 
levels in the gene induction of Stat2 and Irf7 (Figure 15 B and Figure 15 C). Note that all 
genes, Stat1, Stat2, and Irf7 were substantially induced at late-stage infections (16 hours). 
The almost 2-fold more induction of Stat1 gene expression in the wild-type versus TLR3-
deficient OE cells (Figure 15 A), combined with the equivalent levels of induction of 
other genes found in the type I IFN signaling pathway, further proposes a role for STAT1 
in the Chlamydia-mediated synthesis of IFN-β presumably via the type I IFN signaling 
pathway. 
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Figure 15. C. muridarum-induced upregulation of components of the type I IFN 
signaling pathway substantially occur during the late stage of infection and is 
STAT1-dependent 
 OE129 WT, OE TLR3 (-/-) and OE STAT1 (-/-) cells were mock-infected, or 
infected with 10 MOI of C. muridarum (MoPn) for either 6 (white bars) or 16 (black 
bars) hours. Quantitative real-time PCR to measure: (A.) Stat1 mRNA, (B.) Stat2 mRNA, 
or (C.) Irf7 mRNA; was performed using 1 µg of cDNA from total-cell RNA isolated 
from each cell type for each condition with the respective primers (see Table 1). Control 
reactions were set up with β-actin primers to ensure equal loading of RNA. 
63 
The results are presented as mean fold change ± SD; and are representative data from one 
of three individual experiments conducted in duplicate.
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E. C. muridarum-induced type I IFN production is highly dependent on STAT1, but 
is differentially regulated by type I signaling via the IFNAR in OE cells 
 Our data proposes a critical role for STAT1 in the optimal synthesis of IFN-β and, 
presumably, additional type I IFNs during Chlamydia infection of OE cells. We also 
showed that components of the type I IFN signaling pathway were substantially 
upregulated during late-stage Chlamydia infection, interestingly, in a STAT1-dependent 
manner. We hypothesized that, via a positive-feedback loop initiated by early-stage 
TLR3-dependent IFN-β and the IFNAR, STAT1’s role as a mediator of type I IFN 
signaling is crucial for the optimal production or amplification of IFN-β during late-stage 
Chlamydia-infections in OE cells. To examine whether the type I IFN pathway is 
involved in the Chlamydia-induced IFN-β production and in the synthesis of other type I 
IFNs in OE cells, we measured levels in the gene expression of candidate type I IFN 
genes induced by C. muridarum at 6 hr and 16 hr PI, in the presence or absence of 
neutralizing antibody specific for the interferon-α/β receptor (IFNAR). OE129 WT, OE 
TLR3 (-/-) and OE STAT1 (-/-) cells were either mock-infected, or C. muridarum-
infected with or without neutralizing antibody specific for IFNAR. C. muridarum 
infection induced expression of the Ifna2 gene in wild type and TLR3-deficient OE cells 
at early and late times during infection, though the OE cells made substantially more 
Ifna2 early in the infection (6 hr) (Figure 16). As shown, the synthesis of Ifna2 at early 
times during infection appeared to be mostly dependent on STAT1 in the OE cells, since 
OE cells lacking STAT1 were not able to induce Ifna2 gene expression at 6 hr PI (Figure 
18 A). Unlike as seen in the induction of the Ifnb gene during C. muridarum infection 
(Figure 13), the induction of Ifna2 appeared to be attenuated by the presence of TLR3 in 
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OE cells (Figure 16 B); suggesting a possible negative regulation of Ifna2 gene 
expression by stimulation of TLR3 signaling during Chlamydia infection. Blocking the 
type I IFN pathway with IFNAR neutralizing antibody led to significant reductions in the 
C. muridarum-induced synthesis of Ifna2 in both cell types at early and late infection 
(Figure 16), implicating an important role for the type I IFN pathway in the C. 
muridarum-induced synthesis of Ifna2. Interestingly, C. muridarum was still able to 
induce expression of Ifna2 at 16 hr PI in the STAT1-deficient OE cells (Figure 18 A); 
however, its induction appeared to be only minimally dependent on the type I IFN 
pathway in the absence of STAT1. 
 We next examined the role of the type I IFN signaling pathway on the expression 
of Ifna4. C. muridarum infection induced Ifna4 gene expression at 6 and 16 hours PI in 
both wild type and TLR3 deficient OE cells (Figure 17). However, in contrast to what 
was observed with Ifna2 gene expression, most of the Ifna4 gene expression occurred late 
(16 hr) in infection (Figure 17). The expression of Ifna4 was also highly dependent on 
STAT1 at both time points, given that OE cells lacking STAT1 were unable to induce 
Ifna4 gene expression in response to C. muridarum (Figure 18 B). Interestingly, blocking 
the type I IFN pathway with neutralizing antibody specific for IFNAR led to significant 
reductions in wild-type OE cells at the 16 hr time point, but not at the 6 hr time point 
(Figure 17 A). These results suggest that the Chlamydia-induced Ifna4 production in 
wild-type OE cells is highly dependent on STAT1, but occurs through pathways that are 
distinct from the type I IFN signaling pathway via the IFNAR early during infection. 
Also, stimulation of the TLR3 signaling pathway during Chlamydia infection appears to 
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attenuate the expression of Ifna4 in the OE cells, which is demonstrated by the >15 fold 
more induction in the TLR3-deficient OE cells (Figure 17 B). 
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Figure 16. IFNα-2 gene induction occurs preferentially during early-stage 
Chlamydia infection, is IFNAR1-dependent, and is attenuated by TLR3 in OE cells 
 OE129 WT and OE TLR3 (-/-) cells were mock-infected, or infected with 10 MOI 
of C. muridarum (MoPn) for either 6 (white bars) or 16 (black bars) hours with or 
without IFNAR neutralizing antibody (denoted as a-IFNAR), as described in Materials 
and Methods. Quantitative real-time PCR to measure Ifna2 mRNA was performed on 1 
µg of cDNA reverse transcribed from total-cell RNA isolated from each cell type for 
each condition with the respective primers (see Table 1). Control reactions were set up 
with β-actin primers to ensure equal loading of RNA. The results are presented as mean 
fold change ± SD; and are representative data from one of three individual experiments 
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conducted in duplicate. Significance was determined using Student’s T test; *=p value 
<0.05; **=p value <0.005 for the indicated comparisons (MoPn-infected vs MoPn-
infected with IFNAR neutralizing antibody); NS=not significant. 
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Figure 17. IFNα-4 gene induction occurs preferentially during late-stage Chlamydia 
infection, is IFNAR1-dependent, and is attenuated by TLR3 in OE cells 
 OE129 WT and OE TLR3 (-/-) cells were mock-infected, or infected with 10 MOI 
of C. muridarum (MoPn) for either 6 (white bars) or 16 (black bars) hours with or 
without IFNAR neutralizing antibody (denoted as a-IFNAR), as described in Materials 
and Methods. Quantitative real-time PCR to measure Ifna4 mRNA was performed on 1 
µg of cDNA reverse transcribed from total-cell RNA isolated from each cell type for 
each condition with the respective primers (see Table 1). Control reactions were set up 
with β-actin primers to ensure equal loading of RNA. The results are presented as mean 
fold change ± SD; and are representative data from one of three individual experiments 
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conducted in duplicate. Significance was determined using Student’s T test; *=p value 
<0.05 for the indicated comparisons (MoPn-infected vs MoPn-infected with IFNAR 
neutralizing antibody); NS=not significant. 
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Figure 18. STAT1 is required for Ifna2 and Ifna4 gene induction during Chlamydia 
infection in OE cells 
 OE STAT1 (-/-) cells were mock-infected, or infected with 10 MOI of C. 
muridarum (MoPn) for either 6 (white bars) or 16 (black bars) hours with or without 
IFNAR neutralizing antibody (denoted as a-IFNAR), as described in Materials and 
Methods. Quantitative real-time PCR to measure: (A.) Ifna2 mRNA, and (B.) Ifna4 
mRNA was performed on 1 µg of cDNA reverse transcribed from total-cell RNA isolated 
from the cells for each condition with the respective primers (see Table 1). Control 
reactions were set up with β-actin primers to ensure equal loading of RNA. The results 
are presented as mean fold change ± SD; and are representative data from one of three 
individual experiments conducted in duplicate. Significance was determined using 
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Student’s T test for the indicated comparisons (MoPn-infected vs MoPn-infected with 
IFNAR neutralizing antibody); NS=not significant. The cell line represented in this figure 
and cell lines from the previous figures (Figure 16 and Figure 17) were analyzed on the 
same 96-well plate for each time point and indicated primer (see Table 1), and can be 
compared with Ifna2 and Ifna4 levels of the OE WT control cell lines (Figure 16 and 
Figure 17), respectively.  
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 Contrary to what was observed in the C. muridarum-induced synthesis of Ifna 
gene in OE cells, blocking the type I IFN signaling pathway with IFNAR-specific 
antibody had no effect on the induction of the Ifnb gene. As shown in Figure 19, the 
wild-type and TLR3-deficient OE cells both had significant upregulation in the 
expression of the Ifnb gene in response to Chlamydia infection; however, there was no 
reduction in the level of induction of Ifnb when IFNAR was blocked with specific 
antibody (Figure 19). Also, the induction of Ifnb was enhanced by the TLR3 signaling 
pathway, since TLR3-deficient OE cells showed levels of induction that were 10-fold 
lower than wild-type (Figure 19 B). This finding corroborates our earlier studies 
describing a dependence on TLR3 for optimal IFN-β synthesis during C. muridarum 
infection of OE cells [250], and presents the hypothesis that the Chlamydia-induced 
expression and the autocrine/ paracrine regulation of IFN-β involves pathways that are 
distinct from the type-I IFN pathway that signals through IFNAR. 
 We tested this hypothesis by ascertaining the ability of OE cells to induce type I 
IFN genes in response to exogenous recombinant IFN-β. As indicated, wild-type OE cells 
treated with recombinant IFN-β showed substantial inductions in the expression of Ifna2 
(Figure 20 A) and Ifnb (Figure 22 a), but only modest induction of Ifna4 (Figure 21 A); 
however, blocking the type I IFN pathway with antibody specific for IFNAR led to 
significant reductions in the synthesis of early-stageIfna2 and Ifna4 (Figure 20), but not 
Ifnb (Figure 22). Interestingly, TLR3-deficient OEs showed diminished expression of 
Ifnb in response to recombinant IFN-β compared to the wild-type counterparts (Figure 
22). Finally, OE cells lacking STAT1 expressed substantially diminished levels of Ifna2 
(Figure 23 A), and Ifna4 (Figure 23 B) compared to the levels in both WT and TLR3-
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deficient OEs (Figure 20 and Figure 21). There was, though, a modest induction of the 
Ifna4 gene in the STAT1-deficient OE cells after stimulating the cells with recombinant 
IFN-β for 16 hrs; however, the Ifna4 induced appeared to be independent of INFAR 
signaling (Figure 23 B). This data corroborates our findings implicating STAT1 as an 
important mediator in the syntheses of these cytokines, and supports our theory that type 
I IFN production may occur independently of type I IFN signaling via the IFNAR. These 
findings suggest that the IFNAR-dependent type I IFN signaling pathway plays only a 
minor role in the autocrine/ paracrine induction of Ifnb, and supports our hypothesis that 
there are other mechanisms involved in the auto-regulation of IFN-β.
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Figure 19. Late-stage C. muridarum-induced Ifnb gene induction occurs 
independently of type I IFN signaling via the IFNAR in OE cells 
 (A.) OE129 WT, and (B.) OE TLR3 (-/-) cells were mock-infected or infected 
with 10 MOI of C. muridarum (MoPn) for either 6 (white bars) or 16 (black bars) hours 
with or without IFNAR neutralizing antibody (denoted as a-IFNAR), as described in 
Materials and Methods. Quantitative real-time PCR to measure Ifnb mRNA levels was 
performed on 1 µg of cDNA reverse transcribed from total-cell RNA isolated from each 
cell type for each condition with IFN-β primers (see Table 1). Control reactions were set 
up with β-actin primers to ensure equal loading of RNA. The results are presented as 
mean fold change ± SD; and are representative data from one of three individual 
experiments conducted in duplicate.
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Figure 20. Exogenous IFN-β induces early-stage Ifna2 gene expression through the 
type I IFN signaling pathway via the IFNAR in OE cells 
 OE129 WT and OE TLR3 (-/-) cells were mock-infected, or treated with 
exogenous IFN-β with or without IFNAR neutralizing antibody (denoted as a-IFNAR) or 
the isotype control (denoted as a-IgG), for either 6 (white bars) or 16 (black bars) hours 
as described in Materials and Methods. Quantitative real-time PCR to measure Ifna2 
mRNA was performed on 1 µg of cDNA reverse transcribed from total-cell RNA isolated 
from each cell type for each condition with the respective primers (see Table 1). Control 
reactions were set up with β-actin primers to ensure equal loading of RNA. The results 
are presented as mean fold change ± SD; and are representative data from one of three 
77 
individual experiments conducted in duplicate. Significance was determined using 
Student’s T test; *=p value <0.05; **=p value <0.005 for the indicated comparisons 
(IFN-β-treated vs IFN-β-treated with IFNAR neutralizing antibody); NS=not significant.
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Figure 21. Exogenous IFN-β induces minimal Ifna4 gene expression independent of 
the type I IFN signaling pathway via the IFNAR in OE cells 
 OE129 WT and OE TLR3 (-/-) cells were mock-infected, or treated with 
exogenous IFN-β with or without IFNAR neutralizing antibody (denoted as a-IFNAR) or 
the isotype control (denoted as a-IgG), for either 6 (white bars) or 16 (black bars) hours 
as described in Materials and Methods. Quantitative real-time PCR to measure Ifna4 
mRNA was performed on 1 µg of cDNA reverse transcribed from total-cell RNA isolated 
from each cell type for each condition with the respective primers (see Table 1). Control 
reactions were set up with β-actin primers to ensure equal loading of RNA. The results 
are presented as mean fold change ± SD; and are representative data from one of three 
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individual experiments conducted in duplicate. Significance was determined using 
Student’s T test for the indicated comparisons (IFN-β-treated vs IFN-β-treated with 
IFNAR neutralizing antibody); NS=not significant.
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Figure 22. Exogeneous IFN-β upregulates Ifnb gene induction independently of type 
I IFN signaling via the IFNAR in OE cells 
 OE129 WT and OE TLR3 (-/-) cells were mock-infected, or treated with 
exogenous IFN-β with or without IFNAR neutralizing antibody (denoted as a-IFNAR) or 
the isotype control (denoted as a-IgG), for either 6 (white bars) or 16 (black bars) hours, 
as described in Materials and Methods. Quantitative real-time PCR to measure Ifnb 
mRNA levels was performed on 1 µg of cDNA reverse transcribed from total-cell RNA 
isolated from each cell type for each condition with IFN-β primers (see Table 1). Control 
reactions were set up with β-actin primers to ensure equal loading of RNA. The results 
are presented as mean fold change ± SD; and are representative data from one of three 
individual experiments conducted in duplicate. 
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Figure 23. IFN-α subtypes induced with exogenous IFN-β are differentially 
regulated by STAT1 and induction is independent of type I IFN signaling via the 
IFNAR in STAT1-deficient OE cells 
 OE STAT1 (-/-) cells were mock-infected, or treated with exogenous IFN-β with 
or without IFNAR neutralizing antibody (denoted as a-IFNAR) or the isotype control 
(denoted as a-IgG), for either 6 (white bars) or 16 (black bars) hours, as described in 
Materials and Methods. Quantitative real-time PCR to measure: (A.) Ifna2 mRNA, and 
(B.) Ifna4 mRNA was performed on 1 µg of cDNA reverse transcribed from total-cell 
RNA isolated from the cells for each condition with the respective primers (see Table 1). 
Control reactions were set up with β-actin primers to ensure equal loading of RNA. The 
results are presented as mean fold change ± SD; and are representative data from one of 
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three individual experiments conducted in duplicate. Significance was determined using 
Student’s T test for the indicated comparisons (IFN-β-treated vs IFN-β-treated with 
IFNAR neutralizing antibody); NS=not significant. The cell line represented in this figure 
and cell lines from the previous figures (Figure 20 and Figure 21) were analyzed on the 
same 96-well plate for each time point and indicated primer (see Table 1), and can be 
compared with Ifna2 and Ifna4 levels of the OE WT control cell lines (Figure 20 and 
Figure 17), respectively.
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F. Neutralization of IFN-β activity has no effect on Ifnb gene induction during C. 
muridarum infection in OE cells 
 We have established a critical role for STAT1-mediated type I IFN signaling in 
the temporal induction of IFN-α subtypes during C. muridarum infection in OE cells; 
however, our data suggest that type I IFN signaling via the IFNAR plays a minimal role 
in the positive amplification of the IFN-β response in these cells since blocking the 
IFNAR (Figure 19) or upon treatment with exogenous recombinant IFN-β (Figure 22), 
there is relatively no effect on Ifnb gene induction upon Chlamydia infection. 
Furthermore observations taken from the OE cells treated with exogenous recombinant 
IFN-β; in which the Ifnb gene was induced to similar levels in cells treated with or 
without the IFNAR neutralizing antibody compared to mock-infected controls (Figure 
22), implicate the possibility of additional factors that may recognize and that can be 
stimulated by IFN-β during Chlamydia infection.  
 To examine whether IFN-β is directly involved in the Chlamydia-induced IFN-β 
production in OE cells, we measured the levels in the gene expression of Ifnb induced by 
C. muridarum at 6 hr and 16 hr PI, in the presence or absence of neutralizing antibody 
specific for IFN-β. OE129 WT cells were either mock-infected, or C. muridarum-infected 
with or without neutralizing antibody specific for IFN-β. C. muridarum infection induced 
expression of the Ifnb gene in WT OE cells at early and late times during infection 
compared to mock-infected controls, though the OE cells made substantially more Ifnb 
transcripts later in the infection (Figure 24); corroborating previous findings. As shown, 
the expression of Ifnb at early (6 hr) and late (16 hr) times during infection appeared to 
be independent of IFN-β activity in the OE cells, since neutralization of IFN-β had no 
84 
effect on the levels of C. muridarum-induced Ifnb gene transcripts (Figure 24); 
suggesting a minimal role for IFN-β in the positive autocrine regulation of IFN-β during 
Chlamydia infection in oviduct epithelial cells.  
 We previously demonstrated, in OE129 WT cells that we were able to induce Ifnb 
gene expression, that when the cells were treated with exogenous recombinant IFN-β 
blocking the IFNAR with neutralizing antibody prior to the addition of recombinant IFN-
β had no effect on cellular Ifnb gene induction (Figure 22). However, contrary to what we 
observed upon blocking the IFNAR in wild-type OE cells, the blocking of IFN-β 
functional activity by IFN-β specific neutralizing antibody led to a substantial decreases 
in Ifnb gene induction at both early- and late-stage treatment (Figure 25). These 
observations further support the notion that additional factors other than the type I IFN 
receptor (IFNAR) may recognize and be stimulated by IFN-β. These data further supports 
our hypothesis that there are other mechanisms involved in the auto-regulation of IFN-β 
during Chlamydia infection in oviduct epithelial cells. 
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Figure 24. Neutralization of functional IFN-β does not affect C. muridarum-induced 
Ifnb gene induction in OE cells 
 OE129 WT cells were mock-infected or infected with 10 MOI of C. muridarum 
(MoPn) for: (A.) 6 hours, or (B.) 16 hours with or without IFN-β neutralizing antibody 
(denoted as α-IFNβ), as described in Materials and Methods. Quantitative real-time PCR 
to measure Ifnb mRNA levels was performed on 1 µg of cDNA reverse transcribed from 
total-cell RNA isolated from each conditioned cell with IFN-β primers (see Table 1). 
Control reactions were set up with β-actin primers to ensure equal loading of RNA. The 
results are presented as mean fold change ± SD; and are representative data from one of 
three individual experiments conducted in duplicate.
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Figure 25. Neutralization of IFN-β substantially reduces exogeneous IFN-β-induced 
Ifnb gene expression in OE cells 
 OE129 WT cells were mock-infected or infected with 10 MOI of C. muridarum 
(MoPn) for: (A.) 6 hours, or (B.) 16 hours with or without IFN-β neutralizing antibody 
(denoted as α-IFNβ), as described in Materials and Methods. Quantitative real-time PCR 
to measure Ifnb mRNA levels was performed on 1 µg of cDNA reverse transcribed from 
total-cell RNA isolated from each conditioned cell with IFN-β primers (see Table 1). 
Control reactions were set up with β-actin primers to ensure equal loading of RNA. 
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The results are presented as mean fold change ± SD; and are representative data from one 
of three individual experiments conducted in duplicate.
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CHAPTER II. ESTABLISHING THE TEMPORAL ACTIVATION OF STAT1 
AND DETERMINING A ROLE FOR STAT1 IN REGULATING PRO-
INFLAMMATORY CYTOKINE RESPONSES IN C. MURIDARUM-INFECTED 
OE CELLS 
A. IRF3 protein activation is substantially increased during early-intermediate 
stages of C. muridarum infection in OE cells 
 Our previous work established a major role for TLR3 signaling in the production 
of C. muridarum-induced IFN-β in OE cells. It is well known that TLR3 stimulation 
ultimately leads to the activation of key transcription factors involved in efficiently 
initiating Ifnb gene transcription; including IRF3. We hypothesized that the early 
production of IFN-β occurred predominantly through TLR3 stimulation in C. muridarum-
infected OE cells. To test this hypothesis we first examined Irf3 gene expression in wild-
type OE cells via quantitative real-time PCR. The OE129 WT cells were either mock-
infected or infected with 10 MOI of C. muridarum for either 6 hr or 16 hr. As shown, C. 
muridarum-infection displayed no significant induction in Irf3 mRNA levels compared to 
mock-infected controls in wild-type OE cells (Figure 26). We next examined IRF3 
protein activation profiles during C. muridarum-infection in OE cells. OE129 WT cells 
were either mock-infected or infected with 10 MOI of C. muridarum for 2, 4, 6, 8, 12, 16, 
18, or 24 hours. Cell lysates were harvested at the indicated time-points and IRF3 
activation assessed by western blot analysis to detect phosphorylated IRF3 (Figure 27). 
Though mock-infected wild-type OEs expressed basal IRF3 phosphorylation, C. 
muridarum-infection substantially increased IRF3 activation starting at 6 hr PI, and 
became more notable at 8 hr PI. After which, there was a gradual decrease in IRF3 
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activation that was completely diminished by 24 hr PI. These findings suggest that while 
there is no change in Irf3 gene induction in C. muridarum-infected WT OE cells, IRF3 
protein activation is substantially increased; mostly during the early-intermediate stages 
of infection. These observations are similar to a recent study in which IRF3 protein was 
shown to be constitutively expressed and activated at basal levels in unstimulated 
hematopoetic cells [263].
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Figure 26. C. muridarum infection does not induce Irf3 gene transcription in OE 
cells 
 Quantitative real-time PCR was performed using 1 µg of RNA isolated from 
OE129 WT cells that were either mock-infected, or infected with 10 MOI of C. 
muridarum (denoted as MoPn), for 6 hours (white bars) or 16 hours (black bars). IRF3 
primers were used to amplify Irf3 message RNA. Control reactions were set up with β-
actin primers to ensure equal loading of RNA. The results are presented as mean fold 
change ± SD; and are representative data from one of three individual experiments 
conducted in duplicate.
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Figure 27. IRF3 activation is substantially increased at early-intermediate stages of 
C. muridarum infection in OE cells 
 Twenty micrograms of protein from whole cell lysates isolated from OE129 WT 
cells that were either mock-infected (indicated as 0), or infected with C. muridarum at a 
MOI of 10 IFU/ cell for 2, 4, 6, 8, 12, 16, 18 and 24 hours. The proteins were separated 
on a 10% polyacrylamide gel, transferred to a nitrocellulose membrane, and probed with 
antibody to phosphorylated IRF3 (serine residue 396) and β-actin. β-actin served as a 
loading control. The results shown are representative of three independent experiments.
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B. STAT1 protein activation/expression and Stat1 gene expression are disrupted in 
C. muridarum-infected TLR3-deficient OE cells 
 In Chapter I we showed that STAT1 plays a major role in the IFN-β response in 
Chlamydia-infected OE cells. We hypothesized that this was due to its involvement in 
mediating type I IFN signaling. However we showed that Ifnb induction occurs 
independently of the type I IFN signaling pathway via the IFNAR (Figure 19); suggesting 
that STAT1 may play a more prominent role in the IFN-β response during early 
Chlamydia infections. We previously reported that C. muridarum-induced IFN-β 
production in oviduct epithelial cells was dependent on TLR3 signaling [251], and in this 
study we hypothesize that this response is initiated early in infection. We sought to 
ascertain the role of TLR3 signaling on STAT1 activation and expression during 
Chlamydia infections in OE cells. OE129 WT and OE TLR3 (-/-) cells were either mock-
infected, IFN-γ-treated, or infected with 10 IFU/cell C. muridarum prior to analyses by 
RT-PCR for Stat1 gene expression and western blot analyses for STAT1 protein 
expression and activation. C. muridarum infection significantly increased Stat1 mRNA 
levels compared to mock-infected controls in OE129 WT cells; however, Stat1 mRNA 
induction was significantly diminished in TLR3-deficient OEs when compared to the 
wild-type OE cells (Figure 28). We performed western blot analysis to validate the RT-
PCR data (Figure 28). Indeed, the notably diminished induction of Stat1 mRNA in C. 
muridarum-infected OE TLR3 (-/-) cells, correlated to diminished levels of total STAT1 
protein and a corresponding loss of STAT1 protein activation upon C. muridarum 
infection (Figure 29). In Figure 29 the OE129 WT cells exhibited significant increases in 
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both total STAT1 expression and activation (as compared to mock-infected controls) 
upon Chlamydia infection, and these levels were comparable to IFN-γ-treated controls. 
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Figure 28. C. muridarum-induced Stat1 mRNA message is severely reduced in 
TLR3-deficient OE cells 
 Semi-quantitative RT-PCR was performed using 1 µg of cDNA reverse 
transcribed from RNA isolated from OE129 WTs and OE TLR3-deficient cells that were 
mock-infected, infected with C. muridarum at 10 MOI for 24 hours, or treated with 10 
ng/ml of IFN-γ for 4-5 hours. STAT1 primers were used to amplify Stat1 mRNA 
message; and β-actin primers were used to amplify β-actin mRNA message as a loading 
control. 
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Figure 29. STAT1 protein expression and activation are diminished in C. 
muridarum-induced TLR3-deficient OE cells 
 Twenty micrograms of protein in whole cell lysates from: (A.) OE129 WT or (B.) 
TLR3-deficient OEs that were mock-infected, infected with C. muridarum at 10 MOI for 
24 hours, or treated with 10 ng/ml of IFN-γ for 4-5 hours; were separated on a 10% 
polyacrylamide gel. Proteins were transferred to a nitrocellulose membrane and probed 
with antibody to phosphorylated STAT1 (tyrosine residue 701), total STAT1 and β-actin. 
β-actin served as a loading control. The results shown are representative of three 
independent experiments. Densitometric analysis of total STAT1 expression and STAT1 
phosphorylation are shown for each cell line relative to the β-actin control (indicated as 
β-act in the graphs), and C. muridarum-infection indicated by MoPn. 
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C. Early-stage STAT1 activation may contribute to optimal IFN-β production in C. 
muridarum-infected OE cells 
 The previous data shows that STAT1 activation and total expression are TLR3-
dependent (Figure 29) in Chlamydia-infected OE cells. We hypothesized that the 
production of TLR3-dependent IFN-β early during C. muridarum infection was required 
for optimal late-stage production of IFN-β in OE cells, and that the late-stage synthesis 
was predominantly mediated by STAT1 via the IFNAR signaling. However we showed 
that Ifnb induction occurs independently of the type I IFN signaling pathway via the 
IFNAR (Figure 19). This compiled evidence further suggests that STAT1 may play a 
more predominant role in the type I IFN response during early Chlamydia infection in OE 
cells. To further test this hypothesis, we explored the kinetics of STAT1 activation in C. 
muridarum-infected OE cells at various time-points throughout the infection. OE129 WT 
cells were either mock-infected (time-point 0) or infected with 10 MOI of C. muridarum 
for 2, 4, 6, 8, 12, 16, 18, or 24 hours. Cell lysates were harvested at the indicated time-
points and STAT1 activation assessed by western blot analysis to detect phosphorylated 
STAT1. Interestingly, mock-infected wild-type OEs showed pronounced STAT1 
phosphorylation, while C. muridarum-infected wild-type OEs induced notable changes in 
STAT1 phosphorylation at 2 hours and 16 hours post-infection, when compared to the 
other post-infection time-points (Figure 30). Additionally, there were notable changes in 
STAT1 phosphorylation at 6 hours and 24 hours compared to the other post-infection 
time-points (Figure 30).  
 Next, we wanted to determine the effects of inhibiting STAT1 activation at early 
versus late stages of Chlamydia infection on IFN-β production in oviduct epithelial cells. 
97 
OE129 WT cells were infected with C. muridarum alone, or infected with C. muridarum 
and treated with the inhibitor of STAT1 phosphorylation (fludarabine) at 4, 6, or 16 
hours; the amount of IFN-β secreted in supernatants at 24 hr PI was measured by ELISA 
(Figure 31). As shown, IFN-β production was significantly increased upon Chlamydia 
infection in OE129 WT cells (compared to mock-infected cells); however, C. 
muridarum-induced IFN-β was substantially reduced when treated with fludarabine at 4 
hours PI compared to C. muridarum-infection alone (Figure 31). Fludarabine treatment at 
6 hours PI infection slightly reduced IFN-β levels compared to the OE cells infected with 
C. muridarum alone; however, IFN-β levels of OE cells treated with fludarabine at 16 
hours PI were comparable to C. muridarum infection alone (Figure 31). This observation 
suggest that while STAT1 activity may be temporally regulated throughout Chlamydia 
infection in OE cells, it likely has the most dramatic effect on IFN-β synthesis during 
early-stage Chlamydia  infection in OE cells. Our data show that inhibition of STAT1 
phosphorylation early in infection has a more dramatic impact on C. muridarum-induced 
IFN-β synthesis in OE cells than its inhibition at late infection.
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Figure 30. Changes in STAT1 activation during C. muridarum infection in OE cells 
 Twenty micrograms of protein from whole cell lysates isolated from OE129 WT 
cells that were either mock-infected (indicated as 0), or infected with C. muridarum at a 
MOI of 10 IFU/ cell for 2, 4, 6, 8, 12, 16, 18 and 24 hours. The proteins were separated 
on a 10% polyacrylamide gel, transferred to a nitrocellulose membrane, and probed with 
antibody to phosphorylated STAT1 (tyrosine residue 901) and β-actin. β-actin served as a 
loading control. The results shown are representative of three independent experiments.
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Figure 31. Early inhibition of STAT1 activation substantially reduces C. 
muridarum-induced IFN-β production in OE cells 
 OE129 WT cells were mock-infected, infected at a MOI of 10 IFU/ cell with 
either C. muridarum alone (denoted as MoPn), or infected with C. muridarum and treated 
with fludarabine (denoted as Flu) at 4, 6, or 16 hours and all supernatants collected at 24 
hours. ELISA was used to measure infection-induced IFN-β secreted into the 
supernatants of the cells. The data represent mean ± SD and are representative of three 
different experiments conducted in triplicate. Significance was determined using 
Student’s T test; **=p value <0.005 for Mopn 24 hr. versus Flu 4-24hr.
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D. STAT1 plays a central role in IL-6 production in C.muridarum-infected OE cells 
 We have previously shown that C. muridarum-induced OEs produce robust 
amounts of acute-phase proinflammatory cytokines; including IL-6, in a TLR2/MyD88-
dependent manner [155]. Moreover, recent studies from our lab have shown that C. 
muridarum-infected TLR3-deficienct OE cells secrete significantly reduced amounts of 
IL-6 compared to wild-type OEs, but that its synthesis was substantially restored by 
pretreatment with exogenous IFN-β [255]. Based on those studies and our observations in 
this study showing that STAT1 activation is TLR3-dependent (Figure 29), and that early 
STAT1 activation may be required for the IFN-β response (Figure 31), we explored the 
role of STAT1 in the C. muridarum-induced IL-6 response in vitro. We first utilized 
BMDMs derived from wild-type C57BL/6 mice and aged matched STAT1-deficient mice 
to examine the effect of STAT1 deficiency on IL-6 production during C. muridarum-
induction. The WT and STAT1 (-/-) BMDMs were infected with C. muridarum, and the 
amount of IL-6 secreted in supernatants at 24 hr PI was measured (Figure 32). As shown, 
IL-6 production was significantly increased upon Chlamydia infection in WT BMDMs 
compared to mock-infected cells; however, the amount of C. muridarum induced IL-6 
produced at 24hr PI in the STAT1 (-/-) BMDMs was significantly reduced compared to 
the C. muridarum-infected WT BMDMs (Figure 32). Recall, we observed similar 
secretion patterns in the Chlamydia-induced IFN-β response in OE cells isolated from 
wild-type and STAT1-deficient mice.  
 Next, OE129 WT and STAT1 (-/-) OEs were infected with 10 MOI C.muridarum 
and the amount of IL-6 secreted in the supernatants was measured at 24 hr PI. IL-6 
production was significantly decreased in Chlamydia-induced STAT1 (-/-) OEs 
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compared to WT Chlamydia-induced OE cells (Figure 33). To further ascertain the role 
of STAT1 in the Chlamydia-induced IL-6 response in OEs, we knocked-down the 
expression of STAT1 in OE129 WT cells utilizing a ready-made gene silencing plasmid 
specific to the STAT1 gene (control plasmid was used to verify specificity). OE129 WT, 
psiSTAT1 OEs (STAT1 knock-down), and psiLUCGl3 (control plasmid) OEs were 
mock-infected or infected at a MOI of 10 IFU/ cell with C. muridarum, and IL-6 was 
measured in the supernatants at 24 hr (Figure 34). As shown, C. muridarum-induced IL-6 
production was significantly decreased in psiSTAT1 OEs compared to OE129 WT cells 
and OE129 WT OE cells transfected with the psiLUCGl3 control siRNA plasmid (Figure 
34). These findings highlight STAT1 as a major player for the induction of IL-6 in 
Chlamydia-induced OEs; suggesting that STAT1 may play a critical role in regulating 
other acute-phase proinflammatory cytokines. These additional findings corroborates our 
theory that STAT1 may play a key role in cytokine responses during early-stage 
Chlamydia infection, independent of type I IFN signaling via the IFNAR; that contributes 
to modulating the overall immune response in oviduct epithelial cells.
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Figure 32. C. muridarum-induced IL-6 production is significantly reduced in 
STAT1-deficient BMDMs 
 WT BMDMs and STAT1-deficient (STAT1-/-) BMDMs were mock-infected 
and/or infected at a MOI of 10 IFU/ cell with C. muridarum (denoted as MoPn) for 24 
hours. ELISA was used to measure infection-induced IL-6 secreted into the supernatants 
of mock-infected and C. muridarum-infected WT BMDMs and STAT1 (-/-) BMDMs. 
The data represent mean ± SD and are representative of three different experiments 
conducted in triplicate. Significance was determined using Student’s T test; **=p value 
<0.005 for mock-infected WT BMDMs vs MoPn-infected WT BMDMs; and MoPn-
infected WT BMDMs vs MoPn-infected STAT1 (-/-) BMDMs.
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Figure 33. C.muridarum-induced IL-6 production is significantly decreased in 
STAT1-deficient oviduct epithelial cells 
 OEB6 WT cells and STAT1-deficient (STAT1-/-) OE cells were mock-infected 
and/or infected at a MOI of 10 IFU/ cell with C. muridarum (denoted as MoPn) for 24 
hours. ELISA was used to measure infection-induced IL-6 secreted into the supernatants 
of mock-infected and C. muridarum-infected B6 WT cells, and STAT1 (-/-) OE cells. 
The data represent mean ± SD and are representative of three different experiments 
conducted in triplicate. Significance was determined using Student’s T test; **=p value 
<0.005 for mock-infected OE B6 WT vs MoPn-infected OE B6 WT; and MoPn-infected 
OE B6 WT vs MoPn-infected OE STAT1 (-/-) cells.
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Figure 34. STAT1-knockdown oviduct epithelial cells display significantly reduced 
C.muridarum-induced IL-6 production at 24 hours 
 OE129 WT cells were either mock-infected, infected at a MOI of 10 IFU/ cell 
with C. muridarum (denoted as MoPn), or transfected with a STAT1-knockdown plasmid 
(denoted as psiSTAT1) or a control plasmid (denoted as psiLucGl3); respectively, then 
mock-infected or infected with 10 MOI of C. muridarum and all supernatants collected at 
24 hours for ELISA analysis to measure infection-induced IL-6 secretion. The data 
represent mean ± SD and are representative of three different experiments conducted in 
triplicate. Significance was determined using Student’s T test; *=p value <0.05 for 
MoPn-infected OE129 WT vs MoPn-infected psiSTAT1 OEs. 
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 Collectively, the results presented in Chapters I and II show that STAT1 plays a 
critical role in the type I IFN and proinflammatory cytokine responses in oviduct 
epithelial cells during Chlamydia muridarum infections. We show that C. muridarum-
induced STAT1 activation and expression are critical for the synthesis of IFN-β at late-
stages of infection, and that TLR3 also contributes to optimal IFN-β synthesis during 
late-stage Chlamydia infections (Figure 35). In addition we show that C. muridarum 
induced the IFN-α subtypes 2 and 4 in a manner that was STAT1-dependent and that 
required type I IFN signaling through the IFNAR, though at different times during 
infection and attenuated by TLR3 (Figure 36). Interestingly, we show that the C. 
muridarum induced expression of late-stage Ifnb occurred independently of type I IFN 
signaling via the IFNAR (Figure 37). Based on these results we speculated as to what role 
STAT1 would play in the cytokine responses during early stages of infection. We show 
that the proposed “acute” inducer of the type I IFN response, TLR3, was required for 
STAT1 activation and expression during C.muridarum in oviduct epithelial cells, and 
interestingly early inhibition of STAT1 activation showed decreased levels of IFN-β 
secreted from oviduct epithelial cell (Figure 38 A and Figure 38 B). Finally we show that 
C. muridarum infection induced IL-6 secretion in a STAT1-dependent manner (Figure 
39). 
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Figure 35. C. muridarum-induced TLR3 stimulation and STAT1activation are 
required for late-stage IFN-β secretion in OE cells 
 OE cells infected with C. muridarum for 24 hours showed increased STAT1 
activation and expression resulting in increased IFN-β secretion, similarly to the TLR3-
dependent IFN-β response, which may also use STAT1 as a mediator for this response. 
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Figure 36. IFN-α subtypes require STAT1 and the IFNAR for induction, and are 
attenuated by TLR3 during C. muridarum infection in OE cells 
 OE cells infected with C. muridarum showed increased Ifna2 induction early 
during infection and Ifna4 induction late during infection which required STAT1 
(presumably activated by type I IFN signaling via the IFNAR or by an unidentified 
pathway induced by C. muridrum) and  required the IFNAR of the type I IFN signaling 
pathway. Upon inhibiting TLR3 signaling by using TLR3-deficient OE cells there was an 
even more robust induction of the IFN-α subtypes at the indicated times. 
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Figure 37. IFN-β requires STAT1, but not the IFNAR1 for induction during late-
stage C. muridarum infection in OE cells 
 OE cells infected with C. muridarum showed increased Ifnb induction late during 
infection which required STAT1, and in theory, the initial induction and secretion of 
IFN-β to serve as a positive-feedback mediator stimulating the type I IFN receptor. 
However, our results show that increased Ifnb induction late during infection occurred 
independently of the IFNAR of the type I IFN signaling pathway since blocking IFNAR1 
had no effect on the levels of Ifnb gene induction.
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Figure 38. Early-stage STAT1 activation may contribute to optimal “late-stage” 
IFN-β production during C. muridarum infection in OE cells 
 OE cells infected with C. muridarum showed STAT1activation to be TLR3-
dependent (A.). We proposed that TLR3 signaling was an early pathway stimulated by an 
unknown Chlamydia PAMP and was responsible for the “early” production of IFN-β. 
Additionally, when STAT1 activation was inhibited early (4 hours post infection) during 
C. muridarum infection OE cells showed a decrease in late-stage IFN-β secretion (B.).
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Figure 39. STAT1 is required for IL-6 secretion during C. muridarum infection 
 OE cells infected with C. muridarum showed a requirement for STAT1 in the 
secretion of IL-6, an acute-phase proinflammatory cytokine, presumably via an 
unidentified pathway stimulated by C. muridarum.
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DISCUSSION 
 The epithelial cells’ innate immune responses play an important role in the onset 
of pathogenesis in response to Chlamydia infection, and are critical for effective 
clearance of the pathogen [17, 165]. We have previously shown that C. muridarum 
infected OE cells secrete robust levels of TLR-dependent cytokines and chemokines 
involved in the innate immune response, including acute phase inflammatory cytokines 
such as IL-6 and GM-CSF, and the immunomodulatory cytokines such as IFN-β [155]. In 
subsequent reports, we identified TLR3 as the PRR required for Chlamydia-induced IFN-
β production in OE cells by showing that OE cells that were either deficient or disrupted 
in TLR3 signaling, also had severely diminished levels in IFN-β synthesis [250, 251]. 
Here we show that STAT1, a key component of type I IFN signaling pathway, is also 
critical for optimal Chlamydia-induced IFN-β and IL-6 production in OE cells. We also 
show that STAT1 plays a major role in the Chlamydia-induced synthesis of other type I 
IFNs in OE cells during early- and late-stage infection. However, our data suggest that 
STAT1 may have function in type I IFN production, particularly IFN-β production, 
through pathways that are independent of the type I IFN signaling pathway via the 
IFNAR. Evidence in this study also suggests a critical role in the early activation of 
STAT1 that contributes to optimal IFN-β production, and that may contribute to the 
optimal production of IL-6. Furthermore, we report on a unique expression pattern of 
type I IFNs during C. muridarum infection by demonstrating a differential regulation and 
dependence on TLR3 between IFN-β and other type I IFNs. 
 We showed that Stat1 gene expression, STAT1 protein production, and protein 
activation were significantly increased in wild-type OE cells during Chlamydia infection. 
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Furthermore, we provide evidence in this study that suggests STAT1 is critical for 
regulating IFN-β secretion, and restricting C. muridarum replication in induced OE cells 
(Figure 10 and Figure 11, respectively). STAT1 is well established as a mediator 
involved in type I interferon signaling, and in type I interferon-dependent antiviral and 
antimicrobial responses [169, 238]. Additionally, STAT1 has been implicated as a critical 
regulator of type I and type II interferon-dependent control of Chlamydia infections in 
nonhemopoeitic cells [254, 264]. Lad et al, demonstrated that HeLa 229 epithelial cells 
infected with C. trachomatis showed an increased STAT1 activation with a resultant 
reduction in Chlamydia replication compared to STAT1-null and/or STAT1 knockdown 
cells. In that study, they showed that inactivating the effects of IFN-β with neutralizing 
antibody resulted in decreased STAT1 activation; suggesting that STAT1 activity was 
IFN-β-dependent in cervical epithelial cells, and proposing that STAT1 has a role for the 
IFN-β autocrine/paracrine regulatory pathway. 
A. STAT1 is required for C. muridarum-induced IFN-β production during the late 
stage of infection 
 This current study’s investigation into the role of STAT1 seeks to further define 
the role of STAT1 in the pathogenesis of Chlamydia infection by ascertaining whether 
STAT1 contributed to the residual amount of Chlamydia-induced IFN-β in OE cells 
lacking TLR3. We hypothesized that STAT1 is an important mediator in the type I IFN 
response during Chlamydia muridarum infection in OE cells, and that it occurs following 
the TLR3-dependent IFN-β response in order to amplify and sustain the optimal response 
required to presumably combat infection. The results shown in Figure 13 detail the 
significant reduction in Ifnb gene expression during C. muridarum infection of OE cells 
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lacking TLR3 compared to wild type OE cells. However; as shown in Figure 14, the lack 
of STAT1 appeared to have a more dramatic effect in reducing Ifnb synthesis, 
particularly late during infection. These findings were corroborated in ELISA analysis of 
supernatants from STAT1-deficient OEs in which we observed significant reductions in 
C. muridarum-induced IFN-β synthesis compared to wild-type OE cells (Figure 10). 
STAT1 is a critical mediator of type 1 IFN signaling. This data implicates an important 
role for STAT1 in the synthesis of IFN-β during Chlamydia muridarum infections in OE 
cells; and proposes a possible role for STAT1-mediated type I IFN signaling in the 
synthesis of type I IFNs during Chlamydia infection of OE cells. 
B. Temporal and differential upregulation of C. muridarum-induced Ifna gene 
subtypes in OEs requires STAT1, type I IFN-mediated signaling via IFNAR, and is 
attenuated by TLR3 
 We show that STAT1 is critical for IFN-β secretion at 24 hours post-C. 
muridarum infection which represents “late-stage” infection in OE cells for this particular 
laboratory strain. Our hypothesis proposes that this STAT1-dependent IFN-β response 
occurs, presumably late during infection in OE cells, following the acute response 
mediated by TLR3. We also propose that STAT1 mediates a similar response for other 
type I IFNs in OE cells, and that both responses would require type I IFN signaling via 
the IFNAR. The role of IFN-α has been extensively studied and well documented in viral 
infections [112, 168, 265-268]; however, the regulatory mechanisms governing IFNα 
production in Chlamydia infections and other similar intracellular bacterial pathogens are 
poorly understood. In this study we investigated the temporal production of two well 
characterized IFN-α subtypes; IFN-α2 and IFN-α4 [269-272], and the possible roles that 
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both IFNAR-dependent type I IFN signaling (presumably initiated by IFN-β) and STAT1 
play in regulating their expression in OE cells. Our goal was to ascertain whether 
Chlamydia-induced type I IFN signaling via the IFNAR was critical for the induction of 
Ifna gene subtypes, and to determine if STAT1 was germane to this process. Our data 
revealed that there were notable increases in Ifna2 and Ifna4 gene expression in wild-type 
OE cells upon C. muridarum infection and that both sub-types were induced at similar 
levels in a STAT1 dependent manner. Interestingly, Ifna2 was induced at the early stage 
of infection while Ifna4 was significantly induced at the late-stage of infection. Both IFN-
α sub-types’ gene induction were substantially reduced upon inhibition of type I IFN 
signaling by IFNAR neutralizing antibody; implicating the importance of this pathway in 
their production during Chlamydia-infection in OE cells. Our results reveal a suspected 
differential induction of Ifna subtypes in OE cells during C. muridarum infection; 
however, our results differ from the investigations of others which typically identify 
IFNα-4 as the “early subtype” and refer to IFNα-2 as the “late subtype” [195, 269, 273]. 
Nevertheless, other studies show that the temporal induction of these subtypes can vary 
dependent on cell type and mode of induction [274, 275]. 
 We showed that both Ifna2 and Ifnb4 were induced in response to exogenous 
IFN-β, and so we speculate that Chlamydia-induced IFN-β regulates the synthesis of 
other type I IFNs such as the IFN-α subtypes during infection. Other investigations have 
shown that IFN-β-deficient macrophages produce significantly reduced levels of IFN-α in 
response to C. pnuemoniae infection [159]. Interestingly, we showed that OE cells 
lacking TLR3 induced both Ifna2 and Ifna4 at considerably higher levels (40-fold and 25-
fold, respectively) when compared to wild-type OE cells (Figure 16 and Figure 17). 
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These results suggest that TLR3 plays a role in regulating the expression of Ifna 
subtypes, particularly by attenuating its expression during Chlamydia infection. Recent 
studies have identified a plausible mechanism for attenuation of several chemokines and 
cytokines (including type I IFN), that is dependent on TLR signaling in murine 
macrophages. One such mechanism involves a TLR-dependent induction of the 
scaffold/adaptor protein, p62 [276]. Although it is unclear exactly if TLR3 stimulation 
would lead to p62 activation during Chlamydia infection of OE cells, the ability of TLR3 
to attenuate expression of C. muridarum-induced IFN-α via ubiquitin modification by 
way of p62 activity, would suggest that TLR3 is involved in a process to prevent 
excessive inflammatory responses following pathogen/stress signaling. If the syntheses of 
certain type I IFNs are indeed detrimental to the host during Chlamydia infection [163], 
this would represent an important role for TLR3 in Chlamydia pathogenesis because of 
its potential to limit the production of certain type I IFNs; thus limiting genital tract 
damage. This would support our ongoing hypothesis that TLR3 has a critical role in 
controlling the outcome of Chlamydia infection in OE cells because of its ability to 
modulate the expression of numerous innate immune factors [255]. In those studies, we 
described the ability of TLR3 to modulate the immune response during C. muridarum 
infection in OE cells using mechanisms that were dependent and independent of the 
synthesis of IFN-β. Future studies will investigate whether activation of the p62 
scaffold/adaptor protein is diminished or enhanced in absence of TLR3 signaling, and 
whether its function is regulated by IFN-β dependent mechanisms. 
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C. C. muridarum-induced type I IFN and proinflammatory cytokine production is 
highly dependent on STAT1, but is differentially regulated by the type I signaling 
pathway in OE cells 
 Though temporally regulated, the IFN-α subtypes required both STAT1 and the 
IFNAR for optimal induction during C. muridarum infection in OE cells. IFN-β was 
shown to be STAT1-dependent and induced to optimal levels during late-stage C. 
muridarum infection. We tested the hypothesis that the type I IFN signaling pathway, via 
the IFNAR, had a critical role in the synthesis of IFN-β during Chlamydia infection in 
OE cells. Our previous data highlights the importance of the type I IFN signaling 
pathway in the Chlamydia-induced synthesis of IFNα-2 and IFNα-4, and could support 
the conclusions of others describing a critical role for type I IFN signaling pathways in 
the pathogenesis of Chlamydia infection [163, 277]. In those studies, the investigators 
showed reductions in the levels of Chlamydia-induced pathology in both the lung and 
genital-tract infection models in the IFNAR-deficient mice, and attributed those 
reductions in pathogenesis to an increase in IFN-γ production and rapid clearance of 
Chlamydia. The results from those earlier studies implicate synthesis of type I IFNs in 
response to Chlamydia infection as being detrimental to the host. 
 However, we showed that IFNAR-dependent type I IFN signaling pathways had 
virtually no effect in the synthesis of Ifnb during C. muridarum infection in OE cells in 
experiments in which the IFNAR was blocked by neutralization antibody (Figure 19). It 
is possible that the concentration of IFNAR neutralizing antibody used may not have 
been sufficient to block type I IFN signaling; however, we used two times the working 
concentration of the antibody (4.6 ng/ml) and have observed on average that C. 
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muridarum-infected OE WT cells secrete from 450-700 pg/ml of IFN-β at 24 hours post 
infection (Reference Figure 10). Also, the autocrine/paracrine gene induction of Ifnb in 
response to exogenous IFN-β appeared to be completely unaffected by neutralization 
antibody to the IFNAR (Figure 22), whereas both Ifna2 and Ifn4 showed significant but 
differential reductions in their expression when the IFNAR1 was blocked with 
neutralization antibody (Figure 20 and Figure 21). Although all three type I IFNs are 
highly dependent on STAT1 for optimal induction in response to C. muridarum infection, 
our data suggest that the Chlamydia-induced synthesis of IFN-β in OE cells is regulated 
by STAT1-dependent pathways that are distinct from the type I IFN signaling pathway 
that signals through the IFNAR. There are theories of possible intracellular signaling that 
may contribute to initiating interferon-stimulated genes independently of the IFNAR 
receptor. One such possibility involves a known transcription factor required for type I 
IFN production, IRF7. A study has shown that during West Nile viral infections, Irf7 
gene was induced in IFNAR-deficient mouse embryonic fibroblasts were it accumulated 
in the cytoplasm and, additionally, required both IRF3 and IRF9 for induction [278]. It is 
possible that the coordinated functions of intracellular transcription factors induced by 
Chlamydia infection could initiate type I IFN-stimulated gene induction (including type I 
IFNs themselves); independently of the IFNAR in OE cells (Figure 40) as this has be 
shown in myeloid-derived cells [279]. 
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Figure 40. Possible mechanism of STAT1-mediated IFNAR1-indpendent IFN-β 
production by intracellular transcription factors in OE cells during C. muridarum 
infection 
 It is possible in OE cells that C. muridarum infection can stimulate TLR3 
signaling via an unknown PAMP which initiates Irf3 transcription as well as Ifr7 
transcription possibly mediated by STAT1. These transcription factors accumulate, and 
are activated in the cell cytoplasm, possibly via unidentified kinases, and then translocate 
to the nucleus where they initiate type I IFN gene transcription such as Ifnb 
independently of the IFNAR.
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 Furthermore, IFN-β neutralization experiments from this study showed that while 
neutralization of IFN-β had virtually no effect on C. muridarum-induced Ifnb in OE cells 
(Figure 24), neutralizing exogenous IFN-β using an antibody showed a substantial 
reduction in autocrine/ paracrine Ifnb expression when compared to treating cells with 
exogenous recombinant IFN-β alone (Figure 25). This finding was contrary to 
observations obtained from the experiments whereby the OE cell’s IFNAR was blocked 
with neutralizing antibody before treating with exogenous IFN-β. Our data showed that 
the levels of Ifnb induced were unaffected when IFNAR was blocked with neutralizing 
antibody (Figure 22). The differences in IFN-β production between C. muridarum-
infected OEs and exogenous IFN-β treated OEs treated with IFN-β neutralization 
antibody could possibly be explained by the ability of C. muridarum to stimulate 
redundant pathways that contribute to IFN-β production such as the recently identified 
cytosolic nucleic acid sensors, helicase DDX41 and LRRFIP1 [280, 281]. The IFNAR is 
composed of two heterodimeric receptors, IFNAR1 and IFNAR2. In these experiments 
we neutralized the IFNAR1, therefore it is possible that there was incomplete blockage of 
the IFNAR and IFNAR2 could have more affinity for IFN-β thus neutralizing IFNAR1 
would have minimal effect on Ifnb induction during C. muridarum infection in OE cells. 
It is also possible that in OE cells IFN-α subtypes particularly IFN-α2 since its gene was 
induced early compared to IFN-α4 in this study, could initiate STAT1-mediated type I 
IFN signaling leading to amplified IFN-β production. However, IFN-β has been 
implicated as a “prerequisite” for viral-induced interferon synthesis, including IFN-α, in 
mouse embryonic fibroblasts [282]. Nevertheless, our data here suggests that IFN-β may 
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play a role in its autocrine/paracrine regulation possibly through interactions with novel 
receptors and/or components that are independent of signaling through the IFNAR. 
 Our data proposes that STAT1 is critical for the Chlamydia-induced synthesis of 
IFN-β in OE cells, and that the STAT1 activation required for IFN-β synthesis occurs via 
mechanisms that do not involve JAK/STAT activation through type I IFN signaling via 
the IFNAR as required for IFN-α synthesis. Recall, we initially proposed that STAT1’s 
contribution to the type I IFN response occurred predominantly during late-stage 
Chlamydia infection. However, we showed an early-stage induction of Ifna2 during C. 
muridarum infection that was STAT1-dependent; suggesting that STAT1 may play a 
more prominent role early during Chlamydia infection in the synthesis of type I IFN 
and/or other acute-phase cytokines. Our data shows that STAT1 activation and 
expression are TLR3-dependent during C. muridarum infection in OE cells. We have 
provided additional evidence in this study that suggests noticeable changes in STAT1 
activation in OE cells during Chlamydia infection (Figure 30). We also show significant 
reductions in IFN-β secreted from these cells upon early-phase inhibition of STAT1 
activation in Chlamydia-infected OE cells. It is possible in OE cells that Chlamydia 
instead activates STAT1 through direct stimulation of TLR-induced activation of kinases 
such as the p38 MAPK known to phosphorylate STAT1 at serine 727 in macrophages 
upon Listeria stimulation [283]; though tyrosine phosphorylation of STAT1 has also been 
shown to be required for its full transcriptional activity in other cell types [219], or 
through stimulation of TLRs that synthesize immune factors that are known to activate 
JAK/STAT signaling pathways which are independent of the IFNAR. One such immune 
factor that can activate JAK/STAT signaling via an alternative pathway is IL-6. We 
121 
previously showed that C. muridarum induces IL-6 in a TLR2-dependent manner in OE 
cells; and though it can be detected as constitutively expressed in the supernatants of 
mock treated cells, its levels are significantly induced and is detectable in the 
supernatants as early as 3 hours [44, 155]. Others have described activation of 
JAK/STAT signaling pathways through IL-6 binding to the IL-6 receptor in human 
fibrosarcoma cells, resulting in the upregulation of interferon regulatory factor 1 (IRF1) 
gene transcription and potentially type I IFN production [284]. It is possible that upon 
initially encountering Chlamydia, the induction of TLR2-dependent IL-6, or possibly 
TLR3-dependent IL-6 production, leads to the activation of STAT1-dependent Irf1 
induction, that then serves as a primer or co-activator for more robust TLR3-dependent 
IFN-β synthesis in OE cells (Figure 41). Our results show that C. muridarum can induce 
minimal expression of Ifnb in the absence of STAT1 in the OE cells when compared to 
either wild-type or TLR3 deficient OE cells (Figure 13 and Figure 14). The relationship 
between STAT1 deficiency and IL-6 receptor-dependent IRF1 gene transcription has not 
yet been investigated in OE cells, and its impact on the synthesis of Chlamydia-induced 
IFN-β requires further investigation.  
 However, we do describe observations in this report in which STAT1-deficient 
BMDMs and OEs show significantly reduced IL-6 production at 24 hours PI compared to 
wild-type OEs (Figure 32 and Figure 33, respectively). These data were further 
corroborated by siRNA experiments in which C. muridarum-induced STAT1-knockdown 
OE cells also showed a significant decrease in IL-6 production compared to infected 
wild-type OEs and OEs transfected with the control plasmid (Figure 34). Published data 
from our lab has shown a similar decrease in C. muridarum-induced IL-6 production in 
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TLR3-deficient OEs, when compared to C. muridarum infected wild-type OE cells [255]. 
In that earlier investigation, it was suggested that the diminished amount of Chlamydia-
induced IL-6 synthesis in the TLR3-deficient OE cells were the result of a decreased 
level of Tlr2 gene upregulation during Chlamydia infection, when compared to the level 
of Tlr2 gene upregulation in the wild-type OE cells. We hypothesized that the Tlr2 gene 
upregulation during Chlamydia infection occurred through mechanisms that involved 
TLR3-dependent IFN-β synthesis. In additional data from that study we showed that Tlr2 
gene expression was upregulated when the TLR3-deficient OE cells were pre-treated 
with exogenous IFN-β. The current study shows that STAT1 also has a critical role in the 
synthesis of IFN-β and taken together with the importance of TLR3 in the Chlamydia-
induced synthesis of IFN-β in OE cells, these observations highlight a role for STAT1 in 
the positive amplification of other proinflammatory cytokines such as IL-6 during C. 
muridarum infection of OE cells. 
.
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Figure 41. Possible mechanism of early STAT1 activation and optimal IFN-β 
production through C. muridarum-induced IL-6 production in OE cells 
 (A.) Early STAT1 activation, and ultimately, the production of IFN-β could be 
induced in OE cells by 1.) stimulation of TLR2 via a Chlamydia LP or unidentified 
PAMP leading to 2.) the expression and secretion of IL-6 which 3.) binds to and 
stimulates the IL-6α receptor of the same cell or neighboring cells. It is known that IL-6 
signaling propagation requires STAT3; therefore, it is possible that phosphorylated 
STAT3 could recruit, phosphorylated, and form heterodimeric complexes with STAT1, 
and 4.) translocate to the nucleus initiating the transcription of IRF1. IRF1 is known to 
bind STAT1 and could possibly complex with the STAT1-STAT3 homodimer and 5.) 
translocate to the nucleus initiating the transcription of type I IFNs such as IFN-β. (B.) In 
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addition, TLR3 could indirectly contribute to this response by its role in upregulating 
Tlr2 gene expression; presumably leading to increased TLR2 expression on the cell 
surface and ultimately increased IL-6 production. 
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CONCLUSION 
 The present study reveals that STAT1 is a critical component of the Chlamydia-
induced type I interferon and proinflammatory response in oviduct epithelial cells. While 
IFNAR-dependent type I IFN signaling was shown to play a minimal role in IFN-β 
production, STAT1 was shown to be critical for optimal induction of IFN-β during the 
late stages of C. muridarum infection in OE cells; presumably dependent on early STAT1 
activation. In addition, we show that STAT1 plays a critical role in restricting C. 
muridarum replication in OE cells. We show that STAT1 is required for the Chlamydia-
induced induction of several genes involved in the type I IFN signaling pathway such as 
Stat2 and Irf7 during late stages of infection, which is indicative of the type I IFN 
signaling pathway being most active at the latter stages of Chlamydia infection. We 
showed that STAT1 was also critical for the induction of the Ifna subtypes 2 and 4; which 
were revealed to be differentially expressed and negatively regulated by TLR3 signaling 
during C. muridarum infection of OE cells. Our data show that IFN-β appears to be 
regulated in a different manner from other type I IFNs such as IFN-α during C. 
muridarum infection of OE cells, and that Ifna gene subtypes’ induction is dependent on 
type I IFN signaling via the IFNAR signaling pathway. STAT1 was also shown to be 
required for optimal IL-6 production in C. muridarum-induced OE cells. These studies 
implicate STAT1 as a major modulator of the Chlamydia-induced type I interferon and 
IL-6 response in OE cells, and highlights the possible involvement of multiple and 
biphasic STAT1-dependent signaling pathways, TLR signaling pathways, and the 
autocrine/ paracrine pathways involved in regulating their expression. 
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FUTURE DIRECTIONS 
 The studies in this thesis have begun to address the contributions of STAT1 in C. 
muridarum-induced IFN-β production in OE cells, and the mechanisms that govern these 
responses. Elucidation of these pathways of induction and discerning the mechanism(s) 
involved in the regulation of STAT1 induction during infection will be critical for 
increased understanding of the overall pathogenesis of Chlamydia urogential infections, 
and could be advantageous in developing future efficacious therapeutics and/or vaccines. 
However, there are still a number of questions to be answered and observations to be 
investigated based on results presented in Chapters I-II and discussed above. 
 For future investigations it is important to identify additional PRRs in OEs that 
may be induced by C. muridarum and contribute to the IFN-β response. Recently, novel 
cytosolic nucleic acid sensors have been identified in classical immune cells and were 
shown upon stimulation, induce robust amounts of type I IFN. These PRRs were 
identified as  a DNA helicase, DDX41 [281], and a cytosolic nucleic acid-binding 
protein, LRRFIP1 [280]. Primers specific for these newly identified cytosolic nucleic 
acid sensors have been described in the literature, and so it would be advantageous for us 
to first check for expression of these PRRs in OE cells via RT-PCR. If these PRRs are 
expressed in OEs we could then observe any changes in their expression upon C. 
muridarum infection. If obvious changes occur, particularly increased expression, we 
could then knockdown the expressions of either DDX41 or LRRFIP1 through small 
interfering RNA experiments, and analyze IFN-β secretion via ELISA. Additionally, in 
an OE cell line named Bm1.11 we previously showed the expression of NOD1 in 
uninduced conditions and C. muridarum-induced expression of NOD2 [155]. We could 
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further investigate the contributions of these cytosolic nucleotide sensors to Chlamydia-
induced IFN-β synthesis in OE cells by performing similar analysis. 
 We have shown and verified a critical role for STAT1 in regulating the 
production of IFN-β during C. muridarum infection in OE cells. Our original hypothesis 
proposed that STAT1 mediated IFN-β production via type I IFN signaling occurred later 
in infection following the TLR3-dependent IFN-β response. We showed IFN-β synthesis 
to be optimal during late-stage infection, but in an IFNAR1-independent manner. To 
further investigate this phenomenon we could block the IFNAR2 component of the 
IFNAR and observe the effects on IFN-β production in OE cells during C. muridarum 
infection. To further ascertain STAT1’s involvement in this response we could block 
both IFNAR1 and/or IFNAR2 during Chlamydia infection and observe the effects on 
STAT1 activation and expression in OE cells. Additionally, STAT2 activity could be 
analyzed in a similar manner to determine its possible contributions to this response since 
it is a known to form a heterodimeric transcriptional complex with STAT1 that initiates 
the transcription of type I interferons and other interferon-stimulated genes. While our 
observations show dramatic changes in Ifnb expression at both early and late stages of 
Chlamydia infection in STAT1-deficient OEs, we provide additional evidence that 
suggests early activation of STAT1 may play an even more critical role in optimizing the 
IFN-β response in OE cells. We could further investigate the biphasic activation of 
STAT1, and the role it may play in C. muridarum-induced IFN-β production in OE cells. 
As mentioned in the Discussion, it is possible that STAT1 may become activated initially 
by direct C. muridarum stimulation of TLRs, leading to the activation of factors that are 
capable of phosphorylating/activating STAT1. One possibility could be through TLR-
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mediated activation of p38 MAPK, which has been shown as required to phosphorylate 
STAT1 on serine 727 for its full transcriptional activity [208]. We could observe changes 
in p38 activation upon C. muridarum infection in OEs via Western analysis, and 
additionally, observe STAT1 phosphorylation at serine 727 and IFN-β production upon 
inhibiting p38 activation at early times during Chlamydia infection. Moreover, we could 
also neutralize TLR2, the likely TLR candidate in OE cells that may lead to p38 
activation, and observe the effects of blocking TLR2 signaling on STAT1 activation. Our 
studies also highlighted a type I IFN signaling-independent mechanism for C. 
muridarum-induced IFN-β production. To further delineated the activation kinetics of 
STAT1 and address a possible role for STAT1 in that mechanism we could neutralized 
IFNAR and IFN-β, similarly to experiments performed in this study, and observe STAT1 
activation via Western analysis. As discussed above, it has been shown that pathogen-
induced IL-6 signaling leads to the transcription of Irf1, a transcription factor implicated 
in type I IFN gene transcription and known to interact with STAT1 [182, 225]. We could 
explore the relationship between STAT1 deficiency IL-6-dependent Irf11 gene 
transcription, which we hypothesis will be directly correlated since in this study we 
observed decreased levels of IL-6 in STAT1-deficent OEs. Next, we could neutralize the 
IL-6 receptor similar to experiments in this study, and look at changes in STAT1 
activation kinetics. In addition we could neutralize secreted IL-6 using an IL-6 
neutralizing antibody to observe changes in STAT1 activity and type I IFN production. It 
would also be advantageous for us to observe the expression and activation profiles of 
additional STAT proteins such as STAT3 due to its direct involvement in IL-6 signaling 
and its ability to form heterodimers with STAT1 [182, 213]. 
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 We identified a temporal regulation and production of two distinct IFN-α sub-
types, IFN-α2 and IFN-α4 upon C. muridarum infection in OEs. Moreover, we showed 
that production of these cytokines were type I IFN-dependent and attenuated by TLR3, in 
a manner that contrasts the regulation in the IFN-β response to C. muridarum infection. 
To further investigate this phenomena and the direct involvement of IFN-β, we could 
initially neutralize IFN-β and observe the changes in Ifna gene transcription compared to 
observations taken from IFNAR neutralization experiments undertaken in this study. In 
the Discussion we mentioned a TLR3-induced scaffold protein p62 that could possibly 
play a role in targeting IFN-α subtypes for degradation via ubiquitin. We could 
investigate this TLR3-p62-IFN-α axis in OE cells by observing p62 activation at early 
and late times upon C. muridarum-infection in TLR3-deficient cells via Western analysis. 
Additionally, we could investigate the expression and activity of SOCS via RT-PCR and 
Western analyses; particularly SOCS1 and SOCS3 in TLR3-deficient cells to determine 
if they may play a role in TLR3-attenuation of IFN-α2 and IFN-α4. 
 Upon validation of all in vitro studies and experiments it will be critical to utilized 
in vivo murine models to observe C. muridarum-induced phenotypic outcomes. 
Importantly, the use of IFN-β and IFN-α knockout mice would be of significance and 
could identify each cytokine’s specific function in the overall pathogenesis of C. 
muridarum. In addition, STAT1 and TLR2 knockout mice would be of equal importance 
to observe their effects on C. muridarum-induced clearance (i.e. IFN-β production, 
bacterial recovery, leukocyte/lymphocyte recruitment, infection duration, and survival 
rates), and pathology (i.e. oviduct pathology, and uterine pathology). These future 
experiments would provide additional validation and potential mechanisms as to how 
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IFN-β is regulated during C. muridarum infections in OE cells, and how these factors 
contribute to the overall pathogenesis of Chlamydia during urogential infections. 
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American Society of Hematology (ASH) Annual Meeting. Atlanta, GA. December 2007 
(Attendee) 
 
Presenter Indiana University School of Medicine Workshop “Getting You Through” 
  (Spring 2012) 
 
- Charles A. Tindley Accelerated School, Indianapolis, IN Science Interests 
Outreach   Initiative (Spring 2011) 
 
Panelist Summer Research Opportunities Program (SROP) “What I wish I had  
  known before starting graduate school” (Summer 2010) 
 
- Deer Run Elementary School, Indianapolis, IN Outreach Initiative 
“Scientist for a Day” (Spring 2009) 
 
 
Abstracts/Conferences Attended: 
 
Kristen L. Hosey, Jasmine Kamran, and Wilbert A. Derbigny. “The Role of STAT1 
in Chlamydia-induced Type I Interferon Responses in Oviduct Epithelial Cells.” 
National Organization for the Professional Advancement of Black Chemists and 
Chemical Engineers (NOBCChe) Regional Conference November 2011. 
 
Kristen L. Hosey, Jasmine Kamran, and Wilbert A. Derbigny. “The Role of STAT1 
in Chlamydia-induced Type I Interferon Responses.” Annual Biomedical Research 
Conference for Minority Students (ABRCMS) November 2009. 
 
Kristen Hosey, Joseph A. Cameron, and Frank Yang. “Identification of Rrp2-
Controlled Mammalian Infection-Associated Proteins in Borrelia burgdorferi.” 
Mississippi Academy of Sciences (MAS). 2007.  
 
 
Publications: 
 
Kristen L. Hosey, Hu, Sishun and Derbigny, W.A. Role of STAT1 in Chlamydia-
induced type I interferon production in oviduct epithelial cells. Journal of Inflammation 
2013 (submitted) 
 
 Sishun Hu, Hosey, K.L. and Derbigny, W.A. Early-stage TLR3-dependent IFN-β and 
differential signaling pathways are involved in late-stage IFN-β production in Chlamydia-
induced oviduct epithelial cells. (in preparation) 
